Steviol glycoside compositions with reduced surface tension

Information

  • Patent Grant
  • 11701400
  • Patent Number
    11,701,400
  • Date Filed
    Wednesday, April 3, 2019
    5 years ago
  • Date Issued
    Tuesday, July 18, 2023
    10 months ago
Abstract
A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension. Method for reducing surface tension in a steviol glycoside solution includes contacting a steviol glycoside and a surface tension reducing compound.
Description
FIELD

The present disclosure generally relates to steviol glycoside compositions with reduced surface tension having one or more surface tension reducing compounds and one or more steviol glycosides. The present disclosure also discloses methods of making and using these steviol glycoside compositions with reduced surface tension.


BACKGROUND

Traditionally, sugars such as sucrose and fructose have been used to provide a sweetened taste to foods, beverages, pharmaceuticals, and oral hygiene/cosmetic products. While these sugars can provide a taste preferred by consumers, they are caloric. In the last decades, as consumers have become more conscious of caloric intake, there has been increased interest in reducing the amount of caloric sugars in products. One approach to reduce the amount of these sugars has been to replace caloric sugars with non-caloric sweeteners. Non-caloric sweeteners can provide a sweetened taste to foods, beverages, pharmaceuticals, and oral hygiene/cosmetic products without adding calories. Steviol glycosides are an example of high intensity non-caloric sweeteners that can provide a sweetened taste to products without adding calories.


Steviol glycosides are glycosides of steviol, a diterpene compound and are about 150 to 450 times sweeter than sugar. Examples of steviol glycosides are described in WO 2013/096420 (see, e.g., listing in FIG. 1); and in Ohta et. al., “Characterization of Novel Steviol Glycosides from Leaves of Stevia rebaudiana Morita,” J. Appl. Glycosi., 57, 199-209 (2010) (See, e.g., Table 4 at p. 204). Structurally, the diterpene glycosides are characterized by a single base, steviol, and differ by the presence of carbohydrate residues at positions C13 and C19, as presented in FIGS. 2a-2k of PCT Patent Publication WO 2013/096420. Steviol glycosides can include one or more of dulcoside A, stevioside, steviolbioside, rubusoside and/or one or more of rebaudioside A, B, C, D, E, F, G, H, I, J, K, L, M, N, and/or O.


While steviol glycoside can provide a sweetened taste to products, there can be challenges to preparing products with steviol glycoside. In some cases, there may be advantages to preparing a product comprising steviol glycoside composition with reduced surface tension. For example, consumers may prefer a product comprising a steviol glycoside composition with reduced surface tension. Such products can include beverages such as carbonated soda drinks, flavored waters, carbonated flavored waters, and other beverages. Such products can also include dry sweetener compositions, dry drink mixes, and concentrated liquid drink mixes.


Although conventional surfactants can be used to reduce surface tension in food applications, there may be drawbacks to their use with steviol glycoside products. For example, many consumers select steviol glycoside products because these consumers prefer products with natural ingredients. These consumers may not desire a steviol glycoside product with conventional surfactant agents. Likewise, some consumers may prefer a steviol glycoside product made from natural ingredients. Similarly, some consumers may prefer a steviol glycoside product with an ingredient label that lists natural ingredients. Therefore, these consumers may prefer steviol glycoside products with a surface tension reducing compound isolated from a natural source such as a botanical source.


It is an object of the present disclosure to provide a surface tension reducing compound for steviol glycoside compositions with reduced surface tension, for example in the preparation of foods, beverages, pharmaceuticals, and oral hygiene/cosmetic products with steviol glycoside. It is also an object of the present disclosure to provide a surface tension reducing compound isolated from a natural source such as a botanical source.


SUMMARY

The present disclosure generally relates to steviol glycoside compositions comprising a steviol glycoside and a surface tension reducing compound in an amount effect to reduce surface tension. One aspect provides a steviol glycoside composition with reduced surface tension, the composition comprising an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension by at least 10% when compared to a steviol glycoside solution without a surface tension reducing compound. In some aspects, the steviol glycoside composition with reduced surface tension comprises the surface tension reducing compound in an amount effective to reduce surface tension by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without the surface tension reducing compound. In some aspects, the steviol glycoside comprises one or more steviol glycosides selected from the group consisting of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside M, rubusoside, dulcoside A, rebaudioside I, rebaudioside Q, rebaudioside N, rebaudioside O, 1,2-stevioside, 1,3-stevioside, steviol-1,2-bioside, steviol-1,3-bioside, steviol-13-O-glucoside (13-SMG), and steviol-19-O-glucoside (19-SMG). In other aspects, the steviol glycoside comprises one or more steviol glycosides selected from the group consisting of rebaudioside D and rebaudioside M.


In some aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of a quinic acid, caffeic acid, ferulic acid, sinapic acid, p-coumaric acid, an ester of quinic acid, an ester of caffeic acid, an ester of ferulic acid, an ester of sinapic acid, an ester of p-coumaric acid, an ester of caffeic acid and quinic acid, an ester of caffeic acid and quinic acid comprising a single caffeic acid moiety, an ester of caffeic acid and quinic acid comprising more than one caffeic acid moiety, an ester of ferulic acid and quinic acid, an ester of ferulic acid and quinic acid comprising a single ferulic acid moiety, an ester of ferulic acid and quinic acid comprising more than one ferulic acid moiety, an ester of sinapic acid and quinic acid, an ester of sinapic acid and quinic acid comprising a single sinapic acid moiety, an ester of sinapic acid and quinic acid comprising more than one sinapic acid moiety, an ester of p-coumaric acid and quinic acid, an ester of p-coumaric acid and quinic acid comprising a single p-coumaric acid moiety, an ester of p-coumaric acid and quinic acid comprising more than one p-coumaric acid moiety, a caffeic ester of 3-(3,4-dihydroxyphenyl)lactic acid, an ester of caffeic acid and tartaric acid, an ester of caffeic acid and tartaric acid comprising a single caffeic acid moiety, an ester of caffeic acid and tartaric acid comprising more than one caffeic acid moiety, salt thereof and/or isomers thereof. In other aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3-O-feruloylquinic acid, 4-O-feruloylquinic acid, 5-O-feruloylquinic acid, 3,4-diferuloylquinic acid, 3,5-diferuloylquinic acid, 4,5-diferuloylquinic acid, rosmarinic acid, cichoric acid, caftaric acid, monocaffeoyltartaric acid, dicaffeoyltartaric acid and salts and/or isomers thereof. In some aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid. In other aspects, the surface tension reducing compound is enriched for one or more dicaffeoylquinic acids, and salts thereof. In some aspects, the surface tension reducing compound comprises 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more dicaffeoylquinic acids, and salts thereof.


In some aspects, the composition comprises a final concentration of steviol glycoside of between about 1 ppm to about 1000 ppm, about 1 ppm to about 10000 ppm, about 1 ppm to about 100000 ppm, about 1 ppm to about 200000 ppm, or about 1 ppm to about 300000 ppm. In some aspects, the composition comprises a final concentration of steviol glycoside of between about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In other aspects, the composition comprises a final concentration of surface tension reducing compound of between about 1 ppm to about 1000 ppm, about 1 ppm to about 10000 ppm, about 1 ppm to about 100000 ppm, about 1 ppm to about 200000 ppm, or about 1 ppm to about 300000 ppm. In some aspects, the composition comprises a final concentration of surface tension reducing compound of between about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, the composition comprises a ratio of surface tension reducing compound to steviol glycoside of 0.1:1 to 5:1, about 0.5:1 to 4:1, or about 1:1 to 3:1.


In some aspects, the surface tension reducing compound is prepared from a botanical source. In some aspects, the botanical source is selected from the group consisting of eucommoia ulmoides, honeysuckle, nicotiana benthamiana, globe artichoke, cardoon, stevia, stevia rebaudiana, monkfruit, coffee, coffee beans, green coffee beans, tea, white tea, yellow tea, green tea, oolong tea, black tea, red tea, post-fermented tea, bamboo, heather, sunflower, blueberries, cranberries, bilberries, grouseberries, whortleberry, lingonberry, cowberry, huckleberry, grapes, chicory, eastern purple coneflower, echinacea, Eastern pellitory-of-the-wall, Upright pellitory, Lichwort, Greater celandine, Tetterwort, Nipplewort, Swallowwort, Bloodroot, Common nettle, Stinging nettle, Potato, Potato leaves, Eggplant, Aubergine, Tomato, Cherry tomato, Bitter apple, Thorn apple, Sweet potato, apple, Peach, Nectarine, Cherry, Sour cherry, Wild cherry, Apricot, Almond, Plum, Prune, Holly, Yerba mate, Mate, ilex paraguariensis, Guayusa, Yaupon Holly, Kuding, Guarana, Cocoa, Cocoa bean, Cacao, Cacao bean, Kola nut, Kola tree, Cola nut, Cola tree, Hornwort, Ostrich fern, Oriental ostrich fern, Fiddlehead fern, Shuttlecock fern, Oriental ostrich fern, Asian royal fern, Royal fern, Bracken, Brake, Common bracken, Eagle fern, Eastern brakenfern, dandelion, algae, seagrasses, Clove, Cinnamon, Indian bay leaf, Nutmeg, Bay laurel, Bay leaf, Basil, Great basil, Saint-Joseph's-wort, Thyme, Sage, Garden sage, Common sage, Culinary sage, Rosemary, Oregano, Wild marjoram, Marjoram, Sweet marjoram, Knotted marjoram, Pot marjoram, Dill, Anise, Star anise, Fennel, Florence fennel, Tarragon, Estragon, Mugwort, Licorice, Liquorice, Soy, Soybean, Soyabean, Soya vean, Wheat, Common wheat, Rice, Canola, Broccoli, Cauliflower, Cabbage, Bok choy, Kale, Collard greens, Brussels sprouts, Kohlrabi, Winter's bark, Elderflower, Assa-Peixe, Greater burdock, Valerian, and Chamomile. In some aspects, the botanical source is yerba mate, chicory, rosemary, and/or stevia.


One aspect provides a beverage concentrate solution with reduced surface tension, the solution comprising a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension by at least 10% during at least six-fold dilution of the concentrate solution. In some aspects, the steviol glycoside comprises one or more steviol glycosides selected from the group consisting of rebaudioside D and rebaudioside M. In some aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of a quinic acid, caffeic acid, ferulic acid, sinapic acid, p-coumaric acid, an ester of quinic acid, an ester of caffeic acid, an ester of ferulic acid, an ester of sinapic acid, an ester of p-coumaric acid, an ester of caffeic acid and quinic acid, an ester of caffeic acid and quinic acid comprising a single caffeic acid moiety, an ester of caffeic acid and quinic acid comprising more than one caffeic acid moiety, an ester of ferulic acid and quinic acid, an ester of ferulic acid and quinic acid comprising a single ferulic acid moiety, an ester of ferulic acid and quinic acid comprising more than one ferulic acid moiety, an ester of sinapic acid and quinic acid, an ester of sinapic acid and quinic acid comprising a single sinapic acid moiety, an ester of sinapic acid and quinic acid comprising more than one sinapic acid moiety, an ester of p-coumaric acid and quinic acid, an ester of p-coumaric acid and quinic acid comprising a single p-coumaric acid moiety, an ester of p-coumaric acid and quinic acid comprising more than one p-coumaric acid moiety, a caffeic ester of 3-(3,4-dihydroxyphenyl)lactic acid, an ester of caffeic acid and tartaric acid, an ester of caffeic acid and tartaric acid comprising a single caffeic acid moiety, an ester of caffeic acid and tartaric acid comprising more than one caffeic acid moiety, salt thereof and/or isomers thereof. In some aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3-O-feruloylquinic acid, 4-O-feruloylquinic acid, 5-O-feruloylquinic acid, 3,4-diferuloylquinic acid, 3,5-diferuloylquinic acid, 4,5-diferuloylquinic acid, rosmarinic acid, cichoric acid, caftaric acid, monocaffeoyltartaric acid, dicaffeoyltartaric acid and salts and/or isomers thereof. In some aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid. In some aspects, the surface tension reducing compound is enriched for one or more dicaffeoylquinic acids, and salts thereof. In some aspects, the surface tension reducing compound comprises 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more dicaffeoylquinic acids, and salts thereof.


In some aspects, the concentrate solution further comprises a steviol glycoside concentration of between about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, concentrate solution further comprises a concentration of surface tension reducing compound of between about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, the concentrate solution further comprises a concentration of surface tension reducing compound of between about 1000 ppm to about 10000 ppm, about 1000 ppm to about 9000 ppm, 1000 ppm to about 8000 ppm, 1000 ppm to about 7000 ppm, 1000 ppm to about 6000 ppm, 1000 ppm to about 5000 ppm, or 1800 ppm to about 5400 ppm. In some aspects, the concentrate solution further comprises a ratio of surface tension reducing compound to steviol glycoside of 0.1:1 to 5:1, about 0.5:1 to 4:1, or about 1:1 to 3:1.


In some aspects, the concentrate solution further comprises surface tension reducing compound prepared from yerba mate, chicory, rosemary, and/or stevia. In some aspects, the concentrate solution has a pH of 1.5 to 4.


One aspect provides a steviol glycoside composition comprising an admixture of steviol glycoside and surface tension reducing compound, wherein an aqueous solution prepared from the steviol glycoside composition has a reduced surface tension compared to a steviol glycoside solution without surface tension reducing compound. In some aspects, the steviol glycoside comprises one or more steviol glycosides selected from the group consisting of rebaudioside D and rebaudioside M. In some aspects, the steviol glycoside comprises rebaudioside A. In some aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3-O-feruloylquinic acid, 4-O-feruloylquinic acid, 5-O-feruloylquinic acid, 3,4-diferuloylquinic acid, 3,5-diferuloylquinic acid, 4,5-diferuloylquinic acid, rosmarinic acid, cichoric acid, caftaric acid, monocaffeoyltartaric acid, dicaffeoyltartaric acid and salts and/or isomers thereof. In some aspects, the surface tension reducing compound comprises one or more compounds selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid. In some aspects, the surface tension reducing compound is enriched for one or more dicaffeoylquinic acids, and salts thereof. In some aspects, the surface tension reducing compound comprises 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more dicaffeoylquinic acids, and salts thereof. In some aspects, the admixture comprises a ratio of surface tension reducing compound to steviol glycoside of 0.1:1 to 5:1, about 0.5:1 to 4:1, or about 1:1 to 3:1. In some aspects, the surface tension reducing compound is prepared from one or more botanical sources selected from the group consisting of yerba mate, chicory, rosemary, and stevia. In some aspects, the steviol glycoside composition further comprises a buffering system to provide a pH of 1.5 to 4 in to the aqueous solution prepared from the steviol glycoside composition.


One aspect provides a method for reducing surface tension in a steviol glycoside solution, the method comprising contacting a steviol glycoside and a surface tension reducing compound to prepare any of the steviol glycoside compositions with reduced surface tension described above. In some aspects, the surface tension is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without the surface tension reducing compound.


One aspect provides a method for producing a reduced surface tension steviol glycoside solution, the method comprising preparing any of the reduced steviol glycoside compositions described above. In some aspects, the surface tension is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without surface tension reducing compound.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows surface tension measurements for a control solution of a steviol glycoside blend (RM80), a control solution of surface tension reducing compound (isolated from yerba mate), a test solution of steviol glycoside blend with surface tension reducing compound (isolated from yerba mate), and a test solution of steviol glycoside with chlorogenic acid (commercial preparation).



FIG. 2A shows a kinetic surface plot of surface tension over time for a control solution of a steviol glycoside blend (RM80).



FIG. 2B shows a kinetic surface plot of surface tension over time for a test solution of a steviol glycoside blend (RM80) and a surface tension reducing compound (isolated from yerba mate).



FIG. 3 shows surface tension measurements for solutions of rebaudioside A, rebaudioside D, rebaudioside M, and a blend of rebaudioside A (RA80) with and without surface tension reducing compound (isolated from yerba mate).



FIG. 4 shows surface tension measurements for solutions of rebaudioside M (RM80) with and without surface tension reducing compound (rosmarinic acid or cichoric acid).



FIG. 5 shows a kinetic surface plot of surface tension over time for a control solution of rosmarinic acid and a test solution of steviol glycoside (RM80) and rosmarinic acid.



FIG. 6 shows a kinetic surface plot of surface tension over time for a control solution of cichoric acid and a test solution of steviol glycoside (RM80) and cichoric acid.





DETAILED DESCRIPTION

The disclosure relates generally to steviol glycoside compositions with reduced surface tension comprising a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension of the steviol glycoside composition.


In some aspects, the term surface tension refers to a tension of a surface film of a liquid caused by attraction of molecules in the surface layer by a bulk of the liquid which tends to minimize surface area. In other aspects, an aqueous solution with reduced surface tension may exhibit an increase in foam formation upon introduction of a gas, may result in a foam that lasts longer over time, and/or may exhibit a smaller bubble size of the gas in the aqueous solution and/or in the foam. For example, a steviol glycoside composition with a surface tension reducing compound can comprise a reduced surface tension when compared with a similar composition without the surface tension reducing compound.


An example of a steviol glycoside composition with reduced surface tension comprises an aqueous solution of a steviol glycoside and surface tension reducing compound in an amount effective to reduce surface tension. In some aspects, a steviol glycoside composition with reduced surface tension comprises an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension by at least 10%. In other aspects, a steviol glycoside composition with reduced surface tension comprises an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more.


In some aspects, the aqueous solution comprises primarily water. The aqueous solution can also be buffered with any suitable buffering system, including, but not limited to, one or more buffers such as a phosphate, a citrate, ascorbate, lactate, acetate, and the like. The buffer can comprise 1-1000 mM of the anion component. In other aspects, the aqueous solution comprises a citrate/phosphate buffer. In some aspects, citrate/phosphate buffer can have a pH of 2 to 4.


The amounts of steviol glycoside in the steviol glycoside composition and the surface tension reducing composition can be expressed in relation to one another, or to the total amount of steviol glycosides (TSG), such as a weight percentage of the total amount of steviol glycosides (TSG), or to the total amount of surface tension reducing compound, or a ratio, or range of ratios, expressed as a weight percent, or molar percent.


The steviol glycoside composition can include one or more steviol glycosides. In some aspects, the term steviol glycoside refers to Rebaudioside A (Reb A) (CAS 58543-16-1), Rebaudioside B (Reb B) (CAS #58543-17-2), Rebaudioside C (Reb C) (CAS #63550-99-2), Rebaudioside D (Reb D) (CAS #63279-13-0), Rebaudioside E (Reb E) (CAS #63279-14-1), Rebaudioside F (Reb F) (CAS #438045-89-7), Rebaudioside M (Reb M) (CAS #1220616-44-3), Rubusoside (CAS #63849-39-4), Dulcoside A (CAS #64432-06-0), Rebaudioside I (Reb I) (MassBank Record: FU000332), Rebaudioside Q (Reb Q), Rebaudioside 0 (Reb 0), Rebaudioside N (Reb N) (CAS #1220616-46-5), 1,2-Stevioside (CAS #57817-89-7), 1,3-Stevioside (Reb G), Steviol-1,2-Bioside (MassBank Record: FU000299), Steviol-1,3-Bioside, Steviol-13-O-glucoside (13-SMG), Steviol-19-O-glucoside (19-SMG), and steviol glycoside having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or sugar additions (e.g., glucose, rhamnose, and/or xylose), and isomers thereof. See FIG. 1; see also, Steviol Glycosides Chemical and Technical Assessment 69th JECFA, 2007, prepared by Harriet Wallin, Food Agric. Org.


Exemplary steviol glycosides can include rebaudioside M, rebaudioside D, rebaudioside A, rebaudioside B, rebaudioside N, and/or stevioside. In some aspects, one or more of the steviol glycosides are produced by fermentation by an engineered microorganism. For example, rebaudioside D and M can be produced by an engineered organism and then isolated to produce a steviol glycoside composition of primarily rebaudioside D and rebaudioside M as the predominant steviol glycoside species. In other aspects, the steviol glycoside composition can comprise rebaudioside D and rebaudioside M in an amount greater than other steviol glycosides. In some aspects, one or more of the steviol glycosides are isolated from Stevia rebaudiana.


In some aspects, steviol glycosides can include rebaudioside A. For example, steviol glycosides can include blends of rebaudioside A and one or more other steviol glycosides. An example of a blend of rebaudioside A with one or more other steviol glycosides comprises 60% or more rebaudioside A (RA60). Another example of a blend of rebaudioside A with one or more other steviol glycosides comprises 80% or more rebaudioside A (RA80). Another example of a blend of rebaudioside A with one or more other steviol glycosides comprises 95% or more rebaudioside A (RA95). In other aspects, steviol glycosides can include blends of one or more of RebA, RebB, RebC, RebD, RebE, RebF, RebM, rubusoside, dulcoside A, RebI, RebQ, 1,2 stevioside, 1,3 stevioside, steviol-1,2-bioside, steviol-1,3-bioside, 13-SMG, 19-SMG, a tri-glycosylated steviol glycoside, a tetra-glycosylated steviol glycoside, a penta-glycosylated steviol glycoside, a hexa-glycosylated steviol glycoside, a hepta-glycosylated steviol glycoside, and isomers thereof.


In some aspects, the steviol glycoside composition can optionally be described in terms of amounts of rebaudioside M and rebaudioside D. For example, rebaudioside M and rebaudioside D can be present in the composition in a total amount of about 80% (wt) or greater (RM80), 90% (wt) or greater (RM90), or 95% (wt) or greater (RM95), of a total amount steviol glycosides in the composition. Rebaudioside M can be the predominant steviol glycoside in the composition, and can be present, for example, in an amount in the range of about 50% to about 95%, about 70% to about 90%, or about 75% to about 85% of the total amount steviol glycosides in the composition. Rebaudioside D can be in an amount less than Rebaudioside M, such as in an amount in the range of about 5% to about 25%, about 10% to about 20%, or about 10% to about 15% of the total amount steviol glycosides in the composition.


The steviol glycoside composition can optionally be expressed in terms of amounts of other known steviol glycosides that are present in lower amounts. For example, the composition can include one or more of rebaudioside A, rebaudioside B, or stevioside in an amount of about 5% (wt) or less, about 2% (wt) or less, or about 1% (wt) or less, of a total amount of steviol glycosides in the composition.


The amount of steviol glycosides in the steviol glycoside composition with reduced surface tension can vary. Steviol glycosides can be present in the steviol glycoside composition with reduced surface tension in any amount desired for the particular use. For example, steviol glycosides can be present in the steviol glycoside composition with reduced surface tension at a total steviol glycoside concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, steviol glycosides can be present in the steviol glycoside composition with reduced surface tension at a total steviol glycoside concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, steviol glycosides can be present in the steviol glycoside composition with reduced surface tension at a total steviol glycoside concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, steviol glycosides can be present in the steviol glycoside composition with reduced surface tension at a total steviol glycoside concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, steviol glycosides can be present in the steviol glycoside composition with reduced surface tension at a total steviol glycoside concentration of or greater than about 200000 ppm. In some aspects, steviol glycosides can be present in the steviol glycoside composition with reduced surface tension at a total steviol glycoside concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


The amount of an individual steviol glycoside in the steviol glycoside composition with reduced surface tension can vary. For example, an individual steviol glycoside can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, an individual steviol glycoside can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, an individual steviol glycoside can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, an individual steviol glycoside can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, an individual steviol glycoside can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 200000 ppm. In some aspects, an individual steviol glycoside can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis


The amount of an individual steviol glycoside in the steviol glycoside composition with reduced surface tension can vary. For example, RebA can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, RebA can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, RebA can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, RebA can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, RebA can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 200000 ppm. In some aspects, RebA can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


The amount of an individual steviol glycoside in the steviol glycoside composition with reduced surface tension can vary. For example, RebM can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, RebM can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, RebM can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, RebM can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, RebM can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 200000 ppm. In some aspects, RebM can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


In some aspects, the steviol glycosides comprise a high concentration steviol glycoside solution. In some aspects, a high concentration steviol glycoside solution comprises a steviol glycoside solution comprising a total amount of steviol glycosides (TSG) of 1% or more. A high concentration steviol glycoside solution can comprise a steviol glycoside solution comprising a total amount of steviol glycosides (TSG) of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or more. A high concentration steviol glycoside solution can comprise a steviol glycoside solution comprising a total amount of steviol glycosides (TSG) of 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% or more. A high concentration steviol glycoside solution can comprise a steviol glycoside solution comprising a total amount of steviol glycosides (TSG) of 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30% or more. A high concentration steviol glycoside solution can comprise one or more of the steviol glycosides described above. For example a high steviol glycoside solution can comprise one or more of RebA, RebB, RebC, RebD, RebE, RebF, RebM, rubusoside, dulcoside A, RebI, RebQ, 1,2 stevioside, 1,3 stevioside, steviol-1,2-bioside, steviol-1,3-bioside, 13-SMG, 19-SMG, a tri-glycosylated steviol glycoside, a tetra-glycosylated steviol glycoside, a penta-glycosylated steviol glycoside, a hexa-glycosylated steviol glycoside, a hepta-glycosylated steviol glycoside, and isomers thereof.


Examples of surface tension reducing compounds include: caffeic acid, an ester of caffeic acid, an ester of caffeic acid and quinic acid, an ester of caffeic acid and quinic acid comprising a single caffeic acid moiety (e.g., chlorogenic acid, cryptochlorogenic acid, and neochlorogenic acid; structures of each are provided herein), an ester of caffeic acid and quinic acid comprising more than one caffeic acid moiety (e.g., 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid; structures of each are provided herein); ferulic acid, an ester of ferulic acid, an ester of ferulic acid and quinic acid, an ester of ferulic acid and quinic acid comprising a single ferulic acid moiety, an ester of ferulic acid and quinic acid comprising more than one ferulic acid moiety; quinic acid, an ester of quinic acid; tartaric acid, a tartaric acid derivative, an ester of tartaric acid (e.g. caftaric acid or cichoric acid), an ester of a tartaric acid derivative, 3-(3,4-dihydroxyphenyl)lactic acid, a 3-(3,4-dihydroxyphenyl)lactic acid derivative, an ester of 3-(3,4-dihydroxyphenyl)lactic acid (e.g. rosmarinic acid), an ester of a 3-(3,4-dihydroxyphenyl)lactic acid derivative, p-coumaric acid, an ester of p-coumaric acid, an ester of p-coumaric acid and quinic acid, an ester of p-coumaric acid and quinic acid comprising a single p-coumaric acid moiety, an ester of p-coumaric acid and quinic acid comprising more than one p-coumaric acid moiety; sinapic acid, an ester of sinapic acid, an ester of sinapic acid and quinic acid, an ester of sinapic acid and quinic acid comprising a single sinapic acid moiety, an ester of sinapic acid and quinic acid comprising more than one sinapic acid moiety; and 3-O-feruloylquinic acid, 4-O-feruloylquinic acid, 5-O-feruloylquinic acid, 3,4-diferuloylquinic acid, 3,5-diferuloylquinic acid, and 4,5-diferuloylquinic acid.


Caffeic acid has the structure:




embedded image


Ferulic acid has the structure:




embedded image


p-Coumaric acid has the structure:




embedded image


Sinapic acid has the structure:




embedded image


Quinic acid has the structure:




embedded image


3-(3,4-dihydroxyphenyl)lactic acid has the structure:




embedded image


Tartaric acid has the structure:




embedded image



and can be in the D and L forms.


Examples of the esters of the various acids contemplated herein include the ester of caffeic acid and quinic acid, which includes monocaffeoylquinic acids (e.g., chlorogenic acid, neochlorogenic acid, and cryptochlorogenic acid), and dicaffeoylquinic acids (e.g., 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid), and salts thereof:




embedded image


embedded image


embedded image



with 4,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid being most prevalent in the compositions contemplated herein and most prevalent in abundant in stevia, yerba mate, globe artichoke, and green coffee bean.


Examples of the esters of the various acids contemplated herein include the ester of caffeic acid and tartaric acid, which includes cichoric acid having the structure:




embedded image



which has two caffeic acid molecules linked to a tartaric acid core; and caftaric acid having the structure:




embedded image



which has one caffeic acid molecule linked to a tartaric acid core.


Examples of the esters of the various acids contemplated herein include the ester of caffeic acid and 3-(3,4-dihydroxyphenyl)lactic acid including, for example, rosmarinic acid, which has the structure:




embedded image


Each of the caffeic acid, monocaffeoylquinic acids, dicaffeoylquinic acids and other surface tension reducing compounds can be considered weak acids and can each exist in at least one of their conjugate acid form, conjugate base form (e.g., in their salt form), and mixed conjugate acid-conjugate base form, wherein a fraction (e.g., mole fraction) of the compounds exist in the conjugate acid form and another fraction exist in the conjugate base form. The fraction of conjugate acid form to conjugate base form for the caffeic acid, monocaffeoylquinic acids, dicaffeoylquinic acids, and other surface tension reducing compounds will depend on various factors, including the pKa of each compound and the pH of the composition.


Examples of salts of caffeic acid, monocaffeoylquinic acids, dicaffeoylquinic acids, and other surface tension reducing compounds include, but are not limited to, quaternary ammonium, sodium, potassium, lithium, magnesium, and calcium salts of caffeic acid, monocaffeoylquinic acids, dicaffeoylquinic acids, monoferuloylquinic acids, and diferuloylquinic acids, and other surface tension reducing compounds and the like.


In some aspects, the surface tension reducing compound can be enriched for one or more of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids. The term “enriched” refers to an increase in an amount of one of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids relative to one or more other compounds that are present in the surface tension reducing compound. A surface tension reducing compound that is enriched for one or more of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids can reduce surface tension of the steviol glycoside composition with reduced surface tension.


In some aspects, a surface tension reducing compound enriched for one or more dicaffeoylquinic acids can reduce surface tension of the steviol glycoside composition with reduced surface tension. A surface tension reducing compound that is enriched for dicaffeoylquinic acids can comprise 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more, 60% or more, 70% or more, or 80% or more, or 90% or more dicaffeoylquinic acids. In other aspects, a surface tension reducing compound that is enriched for dicaffeoylquinic acids can comprise 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more, 60% or more, 70% or more, or 80% or more, or 90% or more of a combination of one or more of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid, and salts thereof.


The amount of surface tension reducing compound in the steviol glycoside composition with reduced surface tension can vary. Surface tension reducing compound can be present in the steviol glycoside composition with reduced surface tension in any amount desired for the particular use. For example, surface tension reducing compound can be present in the steviol glycoside composition with reduced surface tension at from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, surface tension reducing compound can be present in the steviol glycoside composition with reduced surface tension at about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, surface tension reducing compound can be present in the steviol glycoside composition with reduced surface tension at from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, surface tension reducing compound can be present in the steviol glycoside composition with reduced surface tension at or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, surface tension reducing compound can be present in the steviol glycoside composition with reduced surface tension at or greater than about 200000 ppm. In some aspects, surface tension reducing compound can be present in the steviol glycoside composition with reduced surface tension at or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


The amount of an individual surface tension reducing compound species in the steviol glycoside composition with reduced surface tension can vary. For example, an individual surface tension reducing compound species can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 200000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis


The amount of an individual surface tension reducing compound species in the steviol glycoside composition with reduced surface tension can vary. For example, dicaffeoylquinic acid can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, dicaffeoylquinic acid can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, dicaffeoylquinic acid can be present in the steviol glycoside composition with reduced surface tension at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, dicaffeoylquinic acid can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, dicaffeoylquinic acid can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 200000 ppm. In some aspects, dicaffeoylquinic acid can be present in the steviol glycoside composition with reduced surface tension at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


In some aspects, the surface tension reducing compound may be isolated from botanical sources. Various botanical sources comprise surface tension reducing compounds and surface tension reducing compounds can be isolated from these plants. Some examples of botanical sources from which surface tension reducing compounds can be isolated include eucommoia ulmoides, honeysuckle, nicotiana benthamiana, globe artichoke, cardoon, stevia, stevia rebaudiana, monkfruit, coffee, coffee beans, green coffee beans, tea, white tea, yellow tea, green tea, oolong tea, black tea, red tea, post-fermented tea, bamboo, heather, sunflower, blueberries, cranberries, bilberries, grouseberries, whortleberry, lingonberry, cowberry, huckleberry, grapes, chicory, eastern purple coneflower, echinacea, Eastern pellitory-of-the-wall, Upright pellitory, Lichwort, Greater celandine, Tetterwort, Nipplewort, Swallowwort, Bloodroot, Common nettle, Stinging nettle, Potato, Potato leaves, Eggplant, Aubergine, Tomato, Cherry tomato, Bitter apple, Thorn apple, Sweet potato, apple, Peach, Nectarine, Cherry, Sour cherry, Wild cherry, Apricot, Almond, Plum, Prune, Holly, Yerba mate, Mate, ilex paraguariensis, Guayusa, Yaupon Holly, Kuding, Guarana, Cocoa, Cocoa bean, Cacao, Cacao bean, Kola nut, Kola tree, Cola nut, Cola tree, Hornwort, Ostrich fern, Oriental ostrich fern, Fiddlehead fern, Shuttlecock fern, Oriental ostrich fern, Asian royal fern, Royal fern, Bracken, Brake, Common bracken, Eagle fern, Eastern brakenfern, dandelion, algae, seagrasses, Clove, Cinnamon, Indian bay leaf, Nutmeg, Bay laurel, Bay leaf, Basil, Great basil, Saint-Joseph's-wort, Thyme, Sage, Garden sage, Common sage, Culinary sage, Rosemary, Oregano, Wild marjoram, Marjoram, Sweet marjoram, Knotted marjoram, Pot marjoram, Dill, Anise, Star anise, Fennel, Florence fennel, Tarragon, Estragon, Mugwort, Licorice, Liquorice, Soy, Soybean, Soyabean, Soya vean, Wheat, Common wheat, Rice, Canola, Broccoli, Cauliflower, Cabbage, Bok choy, Kale, Collard greens, Brussels sprouts, Kohlrabi, Winter's bark, Elderflower, Assa-Peixe, Greater burdock, Valerian, and Chamomile. In some aspects, the botanical source is yerba mate, chicory, rosemary, and/or stevia.


Some plants may produce surface tension reducing compounds that are enriched for one or more of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids and can reduce surface tension of the steviol glycoside composition with reduced surface tension. For example, surface tension reducing compounds isolated from yerba mate plant (Ilex paraguariensis) are enriched for dicaffeoylquinic acids and can reduce surface tension of the steviol glycoside composition with reduced surface tension. In other aspects, surface tension reducing compounds isolated from yerba mate plant that are enriched for dicaffeoylquinic acids can comprise 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more, 60% or more, 70% or more, or 80% or more, or 90% or more of a combination of one or more of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid, and salts thereof. For example, surface tension reducing compounds isolated from other plants can be enriched for dicaffeoylquinic acids and can reduce surface tension of the steviol glycoside composition with reduced surface tension. In other aspects, surface tension reducing compounds isolated from other plants that are enriched for dicaffeoylquinic acids can comprise 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more, 60% or more, 70% or more, or 80% or more, or 90% or more of a combination of one or more of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid, and salts thereof.


In some aspects, the surface tension reducing compound can be a blend of surface tension reducing compound isolated from more than one botanical source. The surface tension reducing compound can be a blend of surface tension reducing compound isolated from more than one botanical source.


In some aspects, the ratio of surface tension reducing compound to steviol glycoside in the steviol glycoside composition with reduced surface tension can vary. The ratio of surface tension reducing compound to steviol glycoside in the steviol glycoside composition with reduced surface tension can be in any amount effective to reduce surface tension. For example, the ratio of surface tension reducing compound to steviol glycoside can be from about 0.1:1 to 10:1. In some aspects, the ratio of surface tension reducing compound to steviol glycoside can be in the range of about 0.1:1 to 5:1, about 0.5:1 to 4:1, or about 1:1 to 3:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, or 0.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, or 1.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, or 2.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, or 3.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.5:1, 4.6:1, 4.7:1, 4.8:1, or 4.9:1.


In some aspects, the steviol glycoside composition with reduced surface tension can comprise an surface tension reducing compound in an amount effective to reduce the surface tension compared to a steviol glycoside solution without an surface tension reducing compound. This reduction in surface tension can be at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, or at least 15%. The reduction in surface tension can be at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. The reduction in surface tension can refer to a reduction in initial surface tension of the steviol glycoside composition with reduced surface tension comprising an surface tension reducing compound compared to similar a similar steviol glycoside composition without the surface tension reducing compound. The reduction in surface tension can also refer to a reduction in surface tension of the steviol glycoside composition with reduced surface tension comprising an surface tension reducing compound compared to similar a similar steviol glycoside composition without the surface tension reducing compound over time. The reduction in surface tension can also refer to a reduction in surface tension of the steviol glycoside composition with reduced surface tension comprising an surface tension reducing compound compared to similar a similar steviol glycoside composition without the surface tension reducing compound at equilibrium.


In some aspects, surface tension can be measured by various methods known to the skilled person. A tensiometer can be used to measure surface tension by various methods, including, but not limited to Du Noüy ring method, Du Noüy-Padday method, Wilhelmy plate method, spinning drop method, pendant drop method, bubble pressure method, drop volume method, capillary rise method, stalagmometric method, sessile drop method, vibrational frequency of levitated drops, resonant oscillations of spherical and hemispherical liquid drop.


In some aspects, the steviol glycoside composition with reduced surface tension can comprise additives, flavors, colors, fillers, bulking agents, and other additives including, but not limited to, carbohydrates, polyols, amino acids and their corresponding salts, poly-amino acids and their corresponding salts, sugar acids and their corresponding salts, nucleotides, organic acids, inorganic acids, organic salts including organic acid salts and organic base salts, inorganic salts, bitter compounds, flavorants and flavoring ingredients, astringent compounds, proteins or protein hydrolysates, surfactants, emulsifiers, weighing agents, gums, antioxidants, colorants, flavonoids, alcohols, polymers and combinations thereof, caffeine, quinine, urea, bitter orange oil, naringin, quassia, and salts thereof, vanillin, vanilla extract, mango extract, cinnamon, citrus, coconut, ginger, viridiflorol, almond, menthol (including menthol without mint), cola, lemon, lime, root beer, sarsaparilla, orange, grape skin extract, grape seed extract, chitosan, pectin, pectic, pectinic, polyuronic, polygalacturonic acid, starch, food hydrocolloid or crude extracts thereof (e.g., gum acacia Senegal (Fibergum™), gum acacia seyal, carageenan), poly-L-lysine (e.g., poly-L-a-lysine or poly-L-e-lysine), poly-L-ornithine (e.g., poly-L-a-ornithine or poly-L-e-ornithine), polypropylene glycol, polyethylene glycol, poly(ethylene glycol methyl ether), polyarginine, polyaspartic acid, polyglutamic acid, polyethylene imine, alginic acid, sodium alginate, propylene glycol alginate, and sodium polyethyleneglycolalginate, sodium hexametaphosphate and its salts, and other cationic polymers and anionic polymers. In some aspects, one or more additives is present in the steviol glycoside composition with reduced surface tension at about 0.1 ppm to about 4,000 ppm.


An example of a steviol glycoside composition with reduced surface tension includes a beverage concentrate solution with reduced surface tension comprising a steviol glycoside and an surface tension reducing compound in an amount effective to reduce surface tension by at least 10% during at least six-fold dilution of the concentrate solution. Another example of a beverage concentrate solution with reduced surface tension comprises a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, or at least 15% during at least six-fold dilution of the concentrate solution. Another example of a beverage concentrate solution with reduced surface tension comprises a steviol glycoside and an surface tension reducing compound in an amount effective to reduce surface tension by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% during at least six-fold dilution of the concentrate solution.


In some aspects, the beverage concentrate solution with reduced surface tension comprises a throw syrup for preparing a carbonated soda drink. The beverage concentrate solution with reduced surface tension can also comprise other drink concentrates used to prepare beverages. In other aspects, the beverage concentrate solution with reduced surface tension comprises a throw syrup for preparing a carbonated soda drink in a soda fountain. In some aspects, the beverage concentrate solution with reduced surface tension comprises an aqueous solution. The aqueous solution can comprise primarily water. The aqueous solution can also comprise a buffer such as a citrate/phosphate buffer. The citrate/phosphate buffer can have a pH of 1.5 to 4.


In some aspects, the beverage concentrate solution with reduced surface tension is diluted before use as a beverage. For example, the beverage concentrate solution with reduced surface tension can be diluted in a soda fountain by diluting with a stream of carbonated water as the beverage is dispensed. This diluting of the beverage concentrate solution with reduced surface tension with the stream of carbonated water can dilute the beverage concentrate solution with reduced surface tension by about 6 to 7 times. The surface tension reducing compound can be present in the beverage concentrate solution with reduced surface tension in an effective amount to reduce surface tension during this dilution as the beverage is dispensed. In some aspects, the beverage concentrate solution with reduced surface tension comprises a total steviol glycoside concentration of about 2400 to 4200 ppm. In other aspects, the beverage concentrate solution with reduced surface tension comprises an surface tension reducing compound concentration of 1800 to 5400 ppm. In some aspects, the beverage concentrate solution with reduced surface tension comprises an surface tension reducing compound concentration of 1800 to 1000 ppm.


The beverage concentrate solution with reduced surface tension can also be diluted by mixing with water (or carbonated water) before use as a beverage by a consumer. For example, the beverage concentrate solution with reduced surface tension can be diluted with water or other similar solution such as carbonated water and then mixed. The surface tension reducing compound can be present in the beverage concentrate solution with reduced surface tension in an effective amount to reduce surface tension during the dilution and mixing of the beverage. In some aspects, the beverage concentrate solution with reduced surface tension comprises a total steviol glycoside concentration of about 2400 to 4200 ppm. In other aspects, the beverage concentrate solution with reduced surface tension comprises an surface tension reducing compound concentration of about 1800 to 5400 ppm. In other aspects, the beverage concentrate solution with reduced surface tension comprises an surface tension reducing compound concentration of about 1800 to 1000 ppm.


An example of a steviol glycoside composition with reduced surface tension comprises a dry admixture of steviol glycoside and surface tension reducing compound, wherein an aqueous solution prepared from the dry admixture comprises reduced surface tension compared to an aqueous solution prepared from a dry admixture of steviol glycoside without surface tension reducing compound. In some aspects, surface tension is reduced by at least 10%. In other aspects, surface tension is reduced by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more. In some aspects, initial surface tension is reduced by at least 10%. In other aspects, initial surface tension is reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more. In some aspects, surface tension decreases more quickly over time by at least 10%. In other aspects, surface tension decreases more quickly over time by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more.


In some aspects, an example of a steviol glycoside composition with reduced surface tension comprises a dry admixture of steviol glycoside and surface tension reducing compound, wherein an aqueous solution prepared from the dry admixture has a reduced surface tension compared to a steviol glycoside solution without surface tension reducing compound. This reduction in surface tension can be at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, or at least 15%. The reduction in surface tension can be at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%.


In some aspects, the dry admixture is prepared with an aqueous solution comprising primarily water. The aqueous solution can also be buffered with any suitable buffering system, including, but not limited to, one or more buffers such as a phosphate, a citrate, ascorbate, lactate, acetate, and the like. The buffer can comprise 1-1000 mM of the anion component. In other aspects, the aqueous solution comprises a citrate/phosphate buffer. In some aspects, citrate/phosphate buffer can have a pH of 2 to 4.


The amounts of steviol glycoside in the dry admixture and the surface tension reducing compound can be expressed in relation to one another, or to the total amount of steviol glycosides (TSG), such as a weight percentage of the total amount of steviol glycosides (TSG), or to the total amount of surface tension reducing compound, or a ratio, or range of ratios, expressed as a weight percent, or molar percent.


The dry admixture can include one or more steviol glycosides. In some aspects, the term steviol glycoside refers to Rebaudioside A (Reb A) (CAS #58543-16-1), Rebaudioside B (Reb B) (CAS #58543-17-2), Rebaudioside C (Reb C) (CAS #63550-99-2), Rebaudioside D (Reb D) (CAS #63279-13-0), Rebaudioside E (Reb E) (CAS #63279-14-1), Rebaudioside F (Reb F) (CAS #438045-89-7), Rebaudioside M (Reb M) (CAS #1220616-44-3), Rubusoside (CAS #63849-39-4), Dulcoside A (CAS #64432-06-0), Rebaudioside I (Reb I) (MassBank Record: FU000332), Rebaudioside Q (Reb Q), Rebaudioside 0 (Reb 0), Rebaudioside N (Reb N) (CAS #1220616-46-5), 1,2-Stevioside (CAS #57817-89-7), 1,3-Stevioside (Reb G), Steviol-1,2-Bioside (MassBank Record: FU000299), Steviol-1,3-Bioside, Steviol-13-O-glucoside (13-SMG), Steviol-19-O-glucoside (19-SMG), and steviol glycoside having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or sugar additions (e.g., glucose, rhamnose, and/or xylose), and isomers thereof. See FIG. 1; see also, Steviol Glycosides Chemical and Technical Assessment 69th JECFA, 2007, prepared by Harriet Wallin, Food Agric. Org.


In some aspects, the dry admixture can include rebaudioside A. For example, the dry admixture can include blends of rebaudioside A and one or more other steviol glycosides. An example of a blend of rebaudioside A with one or more other steviol glycosides comprises 60% or more rebaudioside A (RA60). Another example of a blend of rebaudioside A with one or more other steviol glycosides comprises 80% or more rebaudioside A (RA80). Another example of a blend of rebaudioside A with one or more other steviol glycosides comprises 95% or more rebaudioside A (RA95). In other aspects, steviol glycosides can include blends of one or more of RebA, RebB, RebC, RebD, RebE, RebF, RebM, rubusoside, dulcoside A, RebI, RebQ, 1,2 stevioside, 1,3 stevioside, steviol-1,2-bioside, steviol-1,3-bioside, 13-SMG, 19-SMG, a tri-glycosylated steviol glycoside, a tetra-glycosylated steviol glycoside, a penta-glycosylated steviol glycoside, a hexa-glycosylated steviol glycoside, a hepta-glycosylated steviol glycoside, and isomers thereof.


In some aspects, the dry admixture can comprise blends of rebaudioside M and rebaudioside D. For example, rebaudioside M and rebaudioside D can be present in the blend in a total amount of about 80% (wt) or greater, 90% (wt) or greater, or 95% (wt) or greater, of a total amount steviol glycosides (TSG) in the composition. Rebaudioside M can be the predominant steviol glycoside in the blend, and can be present, for example, in an amount in the range of about 50% to about 95%, about 70% to about 90%, or about 75% to about 85% of the total amount steviol glycosides (TSG) in the composition. Rebaudioside D can be in an amount less than Rebaudioside M, such as in an amount in the range of about 5% to about 25%, about 10% to about 20%, or about 10% to about 15% of the total amount of steviol glycosides (TSG) in the composition.


The amount of steviol glycosides in the dry admixture can vary. Steviol glycosides can be present in the dry admixture in any amount desired for the particular use. For example, steviol glycosides can be present in the dry admixture at a total concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, steviol glycosides can be present in the dry admixture at a total concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, steviol glycosides can be present in the dry admixture at a total concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, steviol glycosides can be present in the dry admixture at a total concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, steviol glycosides can be present in the dry admixture at a total concentration of or greater than about 200000 ppm. In some aspects, steviol glycosides can be present in the dry admixture at a total concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


The amount of steviol glycoside in the dry admixture can vary. For example, an individual steviol glycoside can be present in the dry admixture at a concentration of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more.


The amount of an individual steviol glycoside species in the dry admixture can vary. For example, an individual steviol glycoside species can be present in the dry admixture at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, an individual steviol glycoside species can be present in the dry admixture at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, an individual steviol glycoside species can be present in the dry admixture at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, an individual steviol glycoside species can be present in the dry admixture at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, an individual steviol glycoside species can be present in the dry admixture at a concentration of or greater than about 200000 ppm. In some aspects, an individual steviol glycoside species can be present in the dry admixture at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis


The amount of an individual steviol glycoside in the dry admixture can vary. For example, an individual steviol glycoside can be present in the dry admixture at a concentration of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more.


The amount of an individual steviol glycoside species in the dry admixture composition can vary. For example, RebA can be present in the dry admixture at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, RebA can be present in the dry admixture at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, RebA can be present in the dry admixture at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, RebA can be present in the dry admixture at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, RebA can be present in the dry admixture at a concentration of or greater than about 200000 ppm. In some aspects, RebA can be present in the dry admixture at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


The amount of an individual steviol glycoside species in the dry admixture can vary. For example, RebM can be present in the dry admixture at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, RebM can be present in the dry admixture at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, RebM can be present in the dry admixture at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, RebM can be present in the dry admixture at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, RebM can be present in the dry admixture at a concentration of or greater than about 200000 ppm. In some aspects, RebM can be present in the dry admixture at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


In some aspects, the dry admixture comprises steviol glycoside at 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or more by weight. The dry admixture can comprise steviol glycoside at 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% or more by weight. The dry mixture can comprise steviol glycoside at 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30% or more by weight. The dry mixture can comprise steviol glycoside at 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more by weight.


The amount of surface tension reducing compound in the dry admixture can vary. Surface tension reducing compound can be present in the dry admixture in any amount desired for the particular use. For example, surface tension reducing compound can be present in the dry admixture at about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, surface tension reducing compound can be present in the dry admixture at about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, surface tension reducing compound can be present in the dry admixture at about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, surface tension reducing compound can be present in the dry admixture at or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, surface tension reducing compound can be present in the dry admixture at or greater than about 200000 ppm. In some aspects, surface tension reducing compound can be present in the dry admixture at or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


The amount of surface reducing compound in the dry admixture can vary. For example, an individual steviol glycoside can be present in the dry admixture at a concentration of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more.


The amount of an individual surface tension reducing compound species in the dry admixture composition can vary. For example, an individual surface tension reducing compound can be present in the dry admixture at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the dry admixture at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the dry admixture at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the dry admixture at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the dry admixture at a concentration of or greater than about 200000 ppm. In some aspects, an individual surface tension reducing compound species can be present in the dry admixture at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis


In some aspects, the surface tension reducing compound in the dry admixture can be enriched for one or more of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids. The term “enriched” refers to an increase in an amount of one of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids relative to one or more other compounds that are present in the surface tension reducing compound. An surface tension reducing compound that is enriched for one or more of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids can reduce surface tension of the steviol glycoside composition with reduced surface tension. A surface tension reducing compound that is enriched for dicaffeoylquinic acids can comprise 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more, 60% or more, 70% or more, or 80% or more, or 90% or more dicaffeoylquinic acids. In other aspects, a surface tension reducing compound that is enriched for dicaffeoylquinic acids can comprise 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more, 60% or more, 70% or more, or 80% or more, or 90% or more of a combination of one or more of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid, and salts thereof.


The amount of an individual surface tension reducing compound species in the admixture can vary. For example, dicaffeoylquinic acid can be present in the admixture at a concentration from about 1 ppm to about 1000 ppm, from about 1 ppm to about 10000 ppm, from about 1 ppm to about 100000 ppm, from about 1 ppm to about 200000 ppm, or from about 1 ppm to about 300000 ppm. In some aspects, dicaffeoylquinic acid can be present in the admixture at a concentration from about 100 ppm to about 5000 ppm, about 200 ppm to about 5000 ppm, 300 ppm to about 5000 ppm, 400 ppm to about 5000 ppm, 500 ppm to about 5000 ppm, 600 ppm to about 5000 ppm, 700 ppm to about 5000 ppm, 800 ppm to about 5000 ppm, 900 ppm to about 5000 ppm, or 1000 ppm to about 5000 ppm. In some aspects, dicaffeoylquinic acid can be present in the admixture at a concentration from about 1000 ppm to about 5000 ppm, about 2000 ppm to about 5000 ppm, about 3000 ppm to about 5000 ppm, or about 4000 ppm to about 5000 ppm. In some aspects, dicaffeoylquinic acid can be present in the admixture at a concentration of or greater than about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, or 100000 ppm. In some aspects, dicaffeoylquinic acid can be present in the admixture at a concentration of or greater than about 200000 ppm. In some aspects, dicaffeoylquinic acid can be present in the admixture at a concentration of or greater than about 300000 ppm. Unless otherwise expressly stated, ppm is on a by weight basis.


The amount of an individual surface tension reducing compound species in the dry admixture can vary. For example, an individual steviol glycoside species can be present in the dry admixture at a concentration of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more.


In some aspects, the dry admixture comprises surface tension reducing compound at 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or more by weight. The dry admixture can comprise surface tension reducing compound at 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% or more by weight. The dry mixture can comprise surface tension reducing compound at 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30% or more by weight. The dry mixture can comprise surface tension reducing compound at 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more by weight.


In some aspects, the ratio of surface tension reducing compound to steviol glycoside in the dry admixture can vary. The ratio of surface tension reducing compound to steviol glycoside in the dry admixture can be in any amount effective to reduce surface tension. For example, the ratio of surface tension reducing compound to steviol glycoside can be from about 0.1:1 to 10:1. In some aspects, the ratio of surface tension reducing compound to steviol glycoside can be in the range of about 0.1:1 to 5:1, about 0.5:1 to 4:1, or about 1:1 to 3:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, or 0.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, or 1.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, or 2.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, or 3.9:1. In other aspects, the ratio of surface tension reducing compound to steviol glycoside is about 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.5:1, 4.6:1, 4.7:1, 4.8:1, or 4.9:1.


In some aspects, the dry admixture can comprise additives, flavors, colors, fillers, bulking agents, and other additives including, but not limited to those described above. In other aspects, the one or more additives is present in the dry admixture at about 0.1 ppm to about 4,000 ppm. In some aspects, the one or more additives is present in the dry admixture at about 0.1% to about 99% by weight.


In some aspects, the present disclosure is drawn to methods for reducing surface tension in a steviol glycoside solution. For example, a method for reducing surface tension in a steviol glycoside solution can comprise preparing any of the steviol glycoside composition with reduced surface tensions described above. A method for reducing surface tension in a steviol glycoside solution can comprise contacting a steviol glycoside composition and an surface tension reducing compound with an aqueous solution to prepare any of the steviol glycoside composition with reduced surface tensions described above, In other aspects, a method for reducing surface tension in a steviol glycoside solution can comprise contacting a steviol glycoside solution and surface tension reducing solution to prepare one of the steviol glycoside composition with reduced surface tensions described above. In some aspects, a method for reducing surface tension in a steviol glycoside solution can comprise contacting a steviol glycoside solution with dry surface tension reducing compound to prepare one of the steviol glycoside composition with reduced surface tensions described above. Additionally, a method for reducing surface tension in a steviol glycoside solution can comprise contacting a dry steviol glycoside with an surface tension reducing solution to prepare one of the steviol glycoside composition with reduced surface tensions described above. Also, a method for reducing surface tension in a steviol glycoside solution can comprise preparing any of the admixtures of steviol glycoside and surface tension reducing compound as described above and then preparing an aqueous solution using the admixture as described above.


In some aspects, a method for reducing surface tension in a steviol glycoside solution can reduce surface tension by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without an surface tension reducing compound. In some aspects, a method for reducing surface tension in a steviol glycoside solution can reduce surface tension by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% compared to a steviol glycoside solution without an surface tension reducing compound. In other aspects, a method for reducing surface tension in a steviol glycoside solution can reduce initial surface tension by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without an surface tension reducing compound. In some aspects, a method for reducing surface tension in a steviol glycoside solution can reduce surface tension over time by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without an surface tension reducing compound. In some aspects, a method for reducing surface tension in a steviol glycoside solution can reduce surface tension at equilibrium by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without an surface tension reducing compound.


In some aspects, the present disclosure is drawn to methods for reducing surface tension in a steviol glycoside solution. For example, a method for reducing surface tension in a steviol glycoside solution can comprise preparing any of the steviol glycoside composition with reduced surface tensions described above. A method for reducing surface tension in a steviol glycoside solution can comprise contacting a steviol glycoside composition and an surface tension reducing compound with an aqueous solution to prepare any of the steviol glycoside composition with reduced surface tensions described above, In other aspects, a method for reducing surface tension in a steviol glycoside solution can comprise contacting a steviol glycoside solution and a surface tension reducing solution to prepare one of the steviol glycoside composition with reduced surface tensions described above. In some aspects, a method for reducing surface tension in a steviol glycoside solution can comprise contacting a steviol glycoside solution with dry surface tension reducing compound to prepare one of the steviol glycoside composition with reduced surface tensions described above. Additionally, a method for reducing surface tension in a steviol glycoside solution can comprise contacting a dry steviol glycoside with a surface tension reducing solution to prepare one of the steviol glycoside composition with reduced surface tensions described above. Also, a method for reducing surface tension in a steviol glycoside solution can comprise preparing any of the admixtures of steviol glycoside and surface tension reducing compound as described above and then preparing an aqueous solution using the admixture as described above.


In some aspects, a method for reducing surface tension in a steviol glycoside solution can reduce surface tension by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to a steviol glycoside solution without an surface tension reducing compound.


As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. For example, reference to “a steviol glycoside” means one or more steviol glycosides.


EXAMPLES

The following examples are provided to illustrate the disclosure, but are not intended to limit the scope thereof. All parts and percentages are by weight unless otherwise indicated.


Example 1

A series of surface tension assays were carried out to characterize steviol glycoside compositions with and without surface tension reducing compound. A steviol glycoside blend comprising primarily rebaudioside M (RM80) was used. A surface tension reducing compound was prepared from yerba mate. The yerba mate surface tension reducing compound comprised about 50% dicaffeoylquinic acids. Chlorogenic acid was obtained commercially and comprised primarily monocaffeoylquinic acids.


A control solution of 1000 ppm of the RM80 was prepared and labelled as “A”. A control solution of 1000 ppm of the yerba mate surface tension reducing compound was prepared and labelled as “B”. A test solution of 1000 ppm of RM80 blend and 1000 ppm of yerba mate surface tension reducing compound was prepared and labelled as “C”. A test solution of 1000 ppm of RM80 and 3000 ppm of chlorogenic acid was prepared and labelled as “D”. Each solution was also observed visually for foaming. The control solution of 1000 ppm of the yerba mate surface tension reducing compound produced no foam. The test solution of 1000 ppm of RM80 and 1000 ppm of yerba mate surface tension reducing compound produced foam with smaller bubbles than the test solution of 1000 ppm of RM80 and 3000 ppm of chlorogenic acid.


Surface tension measurements of each of the control solutions and test solutions were determined by a Kruss K100MK2 Tensiometer with a roughened platinum and iridium Wilhelmy plate in a 45 mm diameter glass vessel at 20° C. The surface tension of the control solution of 1000 ppm of the RM80 (“A”) was 63.51 mN/m (n=2). The surface tension of the control solution of 1000 ppm of the yerba mate surface tension reducing compound (“B”) was 50.45 mN/m (n=3). The surface tension of the test solution of 1000 ppm of RM80 and 1000 ppm of yerba mate surface tension reducing compound (“C”) was 55.66 mN/m (n=2). The surface tension of the test solution of 1000 ppm of RM80 and 3000 ppm of chlorogenic acid (“D”) was 63.68 mN/m (n=2). The surface tension measurements are shown below in Table 1 and in FIG. 1.












TABLE 1








Surface tension




Surface tension reducing
(mN/m at 20° at


Sample
RebD/RebM
compound
equilibrium)


















A
1000 ppm

63.51


B

1000 ppm of yerba
50.45




mate surface




tension reducing compound


C
1000 ppm
1000 ppm of yerba
55.66




mate surface




tension reducing compound


D
1000 ppm
3000 ppm of commercially
63.68




prepared chlorogenic acid









The surface tension of the control solution of yerba mate surface tension reducing compound was lower than the surface tension of the control solution of RM80. The surface tension of the test solution of RM80 and yerba mate surface tension reducing compound was lower than the surface tension of the control solution of RM80. The surface tension of the test solution of RM80 and chlorogenic acid was similar to the control solution of RM80. The surface tension assays showed that the yerba mate surface tension reducing compound lowered the surface tension of the RM80 solution. The surface tension assays also showed that the chlorogenic acid likely did not affect the surface tension of the RM80 solution. The surface tension assays showed that the yerba mate surface tension reducing compound, which contained the higher ratio of dicaffeoylquinic acids (˜50%), was more effective in reducing the surface tension of the steviol glycoside solution than the chlorogenic acid which comprised primarily monocaffeoylquinic acids.


Kinetic surface plots of surface tension over time were also recorded for the control solution of 1000 ppm of the RM80 and the test solution of 1000 ppm of RM80 and 1000 ppm of yerba mate surface tension reducing compound. FIG. 2A shows the kinetic surface plot of surface tension over time for the control solution of 1000 ppm of the RM80 (“A”). FIG. 2B shows the kinetic surface plot of surface tension over time for the test solution of 1000 ppm of RM80 and 1000 ppm of yerba mate surface tension reducing compound (“C”). The test solution of 1000 ppm of RM80 and 1000 ppm of yerba mate surface tension reducing compound showed significant reduction of surface tension over time indicating active diffusion from the bulk solution to the interface layer. The control solution of 1000 ppm of the RM80 exhibited small dynamic ranges (e.g. <1 mN/m).


Example 2

A series of surface tension assays were carried out to characterize steviol glycoside composition with and without surface tension reducing compounds. Highly purified rebaudioside A (˜95%), rebaudioside D (>99%), rebaudioside M (>99%) were assayed. Rebaudioside A blend derived from stevia leaf at >80% rebaudioside A (RA80) was also used. A surface tension reducing compound was prepared from yerba mate. The yerba mate surface tension reducing compound comprised about 50% dicaffeoylquinic acids.


Control and test solutions were prepared by adding 200 mg of the respective steviol glycoside and/or 200 mg of the surface tension reducing compound to each individual container and then adding 400 ml of ultrapure (18.2 MΩ) water. The individual containers were sealed and shaken to mix. The solutions containing only Reb D or only Reb M were heated to 40-50° C. to fully solubilize the steviol glycoside. The individual containers were allowed to equilibrate at room temperature and then stored at room temperature until assayed. The respective makeup of each solution is shown in Table 2.











TABLE 2







Surface tension




reducing compound




(prepared from yerba




mate with ~50%


Sample
Steviol glycoside
dicaffeoylquinic acids)

















1
500 ppm RebA (~95%)



2
500 ppm RebA (~95%)
500 ppm


3
500 ppm RebD (>99%)



4
500 ppm RebD (>99%)
500 ppm


5
500 ppm RebM (>99%)



6
500 ppm RebM (>99%)
500 ppm


7
500 ppm RA80



8
500 ppm RA80
500 ppm


9




10

500 ppm









Surface tension measurements of each solution were determined by a Kruss K100MK2 Tensiometer with a roughened platinum and iridium Wilhelmy plate (19.9 mm width×0.2 mm thickness×10 mm height) in a 45 mm diameter glass vessel at 20° C. The settings were as follows: detection speed, 10 mm/min; detection sensitivity, 0.005 g; immersion depth 2.0 mm, values, 10 (per log 10 time decade); acquisition, logarithmic; maximum measuring time 21600 s; and vessel, SV10 glass vessel, 43.5 ml, 50 mm. The probe was cleaned with water and flame dried after each measurement. The glass vessel was cleaned thoroughly with water between samples. Deionized water was used as a reference between samples to ensure that no cross-contamination between plate and vessel occurred. Sample containers were gently inverted multiple times to promote thorough mixing. For each sample measurement, 40-50 ml of each sample was transferred to the glass vessel and immediately placed onto the sample stage. Each sample aliquot was magnetically stirred until the surface tension measurement was initiated to prevent surface aging. Samples were measured at equilibrium at 6 h and comprised an average of three data points across all replicates excluding outliers. The surface tension measurements are shown below in Table 3 and in FIG. 3.














TABLE 3







Surface tension
Average






reducing compound
surface tension




(prepared from yerba
measurement

Reduction



Steviol
mate with ~50%
(mN/m at 20°
Standard
in surface


Sample
glycoside
dicaffeoylquinic acids)
at equilibrium)
deviation
tension




















1
500 ppm RebA

59.06623
1.67811




(~95%)


2
500 ppm RebA
500 ppm
50.35869
1.198573
14.74%



(~95%)


3
500 ppm RebD

63.2594
0.765295



(>99%)


4
500 ppm RebD
500 ppm
52.33913
0.773653
17.26%



(>99%)


5
500 ppm RebM

48.09162
1.112912



(>99%)


6
500 ppm RebM
500 ppm
42.46702
0.498555
11.70%



(>99%)


7
500 ppm RA80

58.65504
0.519567


8
500 ppm RA80
500 ppm
48.90965
0.380981
16.61%


9


72.2



10

500 ppm
55.96052
1.15176
22.49%









The surface tension measurements showed that the surface tension was reduced for the rebaudioside A with surface tension reducing compound (Sample 2) compared to the rebaudioside A without surface tension reducing compound (Sample 1). The surface tension was reduced by about 14.74%. The surface tension measurements showed that the surface tension was reduced for the rebaudioside D with surface tension reducing compound (Sample 4) compared to the rebaudioside D without surface tension reducing compound (Sample 3). The surface tension was reduced by about 17.26%. The surface tension measurements showed that the surface tension was reduced for the rebaudioside M with surface tension reducing compound (Sample 6) compared to the rebaudioside M without surface tension reducing compound (Sample 5). The surface tension was reduced by about 11.70%. The surface tension measurements showed that the surface tension was reduced for RA80 with surface tension reducing compound (Sample 8) compared to RA80 without surface tension reducing compound (Sample 7). The surface tension was reduced by about 16.61%. The surface tension measurements showed that the surface tension was reduced for water with surface tension reducing compound (Sample 10) compared to water without surface tension reducing compound (Sample 9). The surface tension was reduced by about 22.49%. The surface tension measurements showed that the surface tension reducing compound reduced surface tension for each of the tested steviol glycoside systems.


Example 3

A series of surface tension assays were carried out to characterize steviol glycoside composition with and without different surface tension reducing compounds. A steviol glycoside blend comprising primarily rebaudioside M (RM80) was used. Cichoric acid and rosmarinic acid were used as surface tension reducing compounds.


A control solution of water was prepared. A control solution of 500 ppm of cichoric acid surface tension reducing compound was prepared. A test solution of 500 ppm of RM80 blend and 500 ppm of cichoric acid surface tension reducing compound was prepared. A control solution of 500 ppm of rosmarinic acid surface tension reducing compound was prepared. A test solution of 500 ppm of RM80 and 500 ppm of rosmarinic acid surface tension reducing compound was prepared.


Surface tension measurements of each of the control solutions and test solutions were determined by a Kruss K100MK2 Tensiometer with a roughened platinum and iridium Wilhelmy plate in a 45 mm diameter glass vessel at 20° C. as described above. The surface tension of the control solution of water was 72.2 mN/m. The surface tension of the solution of 500 ppm of cichoric acid surface tension reducing compound was 71.67 mN/m. The surface tension of the test solution of 500 ppm of RM80 blend and 500 ppm of cichoric acid surface tension reducing compound was 45.46 mN/m. The surface tension of the control solution of 500 ppm of rosmarinic acid surface tension reducing compound was 63.08 mN/m. The surface tension of the test solution of 500 ppm of RM80 and 500 ppm of rosmarinic acid surface tension reducing compound was 45.6 nM/m.


The surface tension measurements are shown below in Table 4 and in FIG. 4.












TABLE 4








Average




Surface tension
surface tension



Steviol
reducing
(mN/m at 20° at


Sample
glycoside
compound
equilibrium)


















Water


72.2


Cichoric

500 ppm of cichoric
71.67


Acid

acid


RM80 +
500 ppm of
500 ppm of cichoric
45.46


cichoric
RM80
acid


acid


Rosmarinic

500 ppm of rosmarinic
63.08


acid

acid


RM80 +
500 ppm of
500 ppm of rosmarinic
45.6


rosmarinic
RM80
acid


acid









The surface tension of the control cichoric acid surface tension reducing compound was about the same as the water control, showing that the cichoric acid surface tension reducing compound did not significantly reduce the surface tension. The surface tension of the test solution of 500 ppm of RM80 blend and 500 ppm of cichoric acid surface tension reducing compound was reduced (45.46 mN/m) from the water control (72.2 mN/m) and the control cichoric acid surface tension reducing compound (45.46 mN/m), showing that the test solution had a reduced surface tension compared to the control solutions. The surface tension of the control rosmarinic acid surface tension reducing compound (63.08 mN/m) was reduced compared to the water control (72.2 mN/m), showing that the rosmarinic acid surface tension reducing compound did reduce the surface tension. The surface tension of the test solution of 500 ppm of RM80 blend and 500 ppm of rosmarinic acid surface tension reducing compound was reduced (45.6 mN/m) from the water control (72.2 mN/m) and the control rosmarinic acid surface tension reducing compound (63.08 mN/m), showing that the test solution had a reduced surface tension compared to the control solutions.


Kinetic surface plots of surface tension over time were also recorded for the control solution of 500 ppm of the rosmarinic acid surface tension reducing compound and the test solution of 500 ppm of RM80 and 500 ppm of rosmarinic surface tension reducing compound. FIG. 5 shows the kinetic surface plot of surface tension over time for the control solution of 500 ppm of the rosmarinic acid and the test solution of 500 ppm of RM80 and 500 ppm of rosmarinic surface tension reducing compound. FIG. 6 shows the kinetic surface plot of surface tension over time for the control solution of 500 ppm of the cichoric acid and the test solution of 500 ppm of RM80 and 500 ppm of cichoric acid surface tension reducing compound.

Claims
  • 1. A steviol glycoside composition with reduced surface tension, the composition comprising an aqueous solution of: a steviol glycoside; andat least 1% by weight of a surface tension reducing compound, the surface tension reducing compound comprising(i) one or more monocaffeoylquinic acids or salts thereof;(ii) at least 10% by weight of one or more dicaffeoylquinic acids or salts thereof and(iii) at least one of an ester of ferulic acid and quinic acid, an ester of sinapic acid and quinic acid, an ester of p-coumaric acid and quinic acid, an ester of caffeic acid and 3-(3,4-dihydroxyphenyl)lactic acid, an ester of caffeic acid and tartaric acid, and isomers thereof,wherein the aqueous solution comprises a 1:0.5 to 1:4 ratio by weight of steviol glycoside to the surface tension reducing compound.
  • 2. The composition of claim 1, wherein the surface tension reducing compound comprise at least one of neochlorogenic acid, cryptochlorogenic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3-O-feruloylquinic acid, 4-0-feruloylquinic acid, 5-0-feruloylquinic acid, 3,4-diferuloylquinic acid, 3,5-diferuloylquinic acid, 4,5-diferuloylquinic acid, rosmarinic acid, cichoric acid, caftaric acid, monocaffeoyltartaric acid, dicaffeoyltartaric acid and isomers thereof.
  • 3. The composition of claim 1, wherein the surface tension reducing compound comprises at least 20% by weight of one or more dicaffeoylquinic acids or salts thereof.
  • 4. The composition of claim 1, wherein the surface tension reducing compound comprises at least 40% dicaffeoylquinic acids or salts thereof.
  • 5. The composition of claim 1, wherein the composition comprises between about 100 ppm and about 5000 ppm steviol glycoside.
  • 6. The composition of claim 1, wherein the composition comprises rebaudioside D or rebaudioside M.
  • 7. The composition of claim 1, wherein the steviol glycoside comprises between about 50% to about 95% rebaudioside M.
  • 8. The composition of claim 1, wherein the steviol glycoside comprises between about 5% and about 25% rebaudioside D.
  • 9. The composition of claim 1, wherein the total steviol glycoside concentration is at least 1% by weight.
  • 10. The composition of claim 1, wherein the aqueous solution comprises a 1:1 to 1:3 ratio by weight of steviol glycoside to the surface tension reducing compound.
  • 11. The composition of claim 1, wherein the aqueous solution comprises a 1:1 to 1:3 ratio by weight of steviol glycoside to total concentration of esters of caffeic acid and quinic acid, esters of ferulic acid and quinic acid, esters of sinapic acid and quinic acid, esters of p-coumaric acid and quinic acid, esters of caffeic acid and 3-(3,4-dihydroxyphenyl)lactic acid, and esters of caffeic acid and tartaric acid.
  • 12. A beverage comprising the composition of claim 1.
  • 13. A beverage concentrate solution with reduced surface tension, the solution comprising: a steviol glycoside; anda surface tension reducing compound in an amount effective to reduce surface tension by at least 10% during at least six-fold dilution of the concentrate, the surface tension reducing compound comprising(i) one or more monocaffeoylquinic acids or salts thereof;(ii) at least 10% by weight of one or more dicaffeoylquinic acids or salts thereof and(iii) at least one of an ester of ferulic acid and quinic acid, an ester of sinapic acid and quinic acid, an ester of p-coumaric acid and quinic acid, an ester of caffeic acid and 3-(3,4-dihydroxyphenyl)lactic acid, an ester of caffeic acid and tartaric acid, and isomers thereof,wherein the solution comprises a 1:0.5 to 1:4 ratio by weight of steviol glycoside to the surface tension reducing compound.
  • 14. The solution of claim 13, wherein the solution comprises about 2400 to about 4200 ppm steviol glycoside.
  • 15. The solution of claim 13, wherein the solution comprises about 1800 to about 5400 ppm surface tension reducing compound.
  • 16. The solution of claim 13, wherein the solution comprises a 1:1 to 1:3 ratio by weight of steviol glycoside to total concentration of esters of caffeic acid and quinic acid, esters of ferulic acid and quinic acid, esters of sinapic acid and quinic acid, esters of p-coumaric acid and quinic acid, esters of caffeic acid and 3-(3,4-dihydroxyphenyl)lactic acid, and esters of caffeic acid and tartaric acid.
  • 17. The solution of claim 13, wherein the surface tension reducing compound comprises at least 20% dicaffeoylquinic acid.
  • 18. The solution of claim 13, wherein the steviol glycoside comprises greater than 80% rebaudioside M and rebaudioside D.
  • 19. The solution of claim 13, wherein the solution additionally includes a buffer and has a pH between 1.5 and 4.
  • 20. A method for reducing surface tension in a steviol glycoside composition, the method comprising: adding to a solution comprising a steviol glycoside a surface tension reducing compound comprising (i) one or more monocaffeoylquinic acids or salts thereof; (ii) at least 10% by weight of one or more dicaffeoylquinic acids or salts thereof; and (iii) at least one of an ester of ferulic acid and quinic acid, an ester of sinapic acid and quinic acid, an ester of p-coumaric acid and quinic acid, an ester of caffeic acid and 3-(3,4-dihydroxyphenyl)lactic acid, an ester of caffeic acid and tartaric acid, and isomers thereof, wherein the surface tension reducing compound is added in an amount such that the resulting composition comprises a 1:0.5 to 1:4 ratio by weight of steviol glycoside to the surface tension reducing compound and such that the resulting composition comprises at least 1% by weight of the surface tension reducing compound.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of International Application No. PCT/US2018/054804, filed Oct. 8, 2018, entitled “Steviol Glycoside Compositions with Reduced Surface Tension”, which claims the benefit of U.S. Provisional Application No. 62/569,279, filed Oct. 6, 2017, and entitled “Steviol Glycoside Solubility Enhancers”, each of which is hereby incorporated by reference in its entirety. This application claims the benefit of U.S. Provisional Application No. 62/676,722, filed May 25, 2018, and entitled “Methods for Making Yerba Mate Extract Composition”, which application is hereby incorporated by reference in its entirety.

US Referenced Citations (224)
Number Name Date Kind
3916028 Lee Oct 1975 A
3924017 Lee Dec 1975 A
4082858 Morita Apr 1978 A
4312856 Korduner Jan 1982 A
4495170 Beyts Jan 1985 A
4710583 Chmurny Dec 1987 A
4853237 Prinkkila Aug 1989 A
4906480 Kashket Mar 1990 A
5336513 Riemer Aug 1994 A
5681569 Kuznicki Oct 1997 A
5788971 Togasaki Aug 1998 A
5888549 Buchholz Mar 1999 A
6022576 Cirigliano Feb 2000 A
6337095 Jain Jan 2002 B1
6426112 Boatright Jul 2002 B1
6475544 Hiramoto Nov 2002 B1
6589588 Wester Jul 2003 B1
6635774 Roden Oct 2003 B2
6900240 Empie May 2005 B2
6989171 Portman Jan 2006 B2
7279184 Gow Oct 2007 B2
7291352 Gow Nov 2007 B2
7294353 Gow Nov 2007 B2
7651717 Shioya Jan 2010 B2
7727565 Jani Jun 2010 B2
7750053 Suzuki Jul 2010 B2
7767238 Roy Aug 2010 B2
7838044 Abelyan Nov 2010 B2
7879376 Boghani Feb 2011 B2
7939563 Suzuki May 2011 B2
8017168 Prakash Sep 2011 B2
8076491 Karanewsky Dec 2011 B2
8088428 Yamane Jan 2012 B2
8092795 Tsuchiya Jan 2012 B2
8178148 Fujii May 2012 B2
8197875 Chien Jun 2012 B2
8241680 Williams Aug 2012 B2
8337929 Ogura Dec 2012 B2
8367137 Prakash Feb 2013 B2
8512789 Prakash Aug 2013 B2
8524304 Prakash Sep 2013 B2
8530527 Markosyan Sep 2013 B2
8703228 Boghani Apr 2014 B2
8940350 Prakash Jan 2015 B2
8940351 Prakash Jan 2015 B2
8956678 Prakash Feb 2015 B2
9011956 Prakash Apr 2015 B2
9060537 Mutilangi Jun 2015 B2
9101160 Prakash Aug 2015 B2
9101161 Prakash Aug 2015 B2
9131719 Backes Sep 2015 B2
9133229 Lee Sep 2015 B2
9144251 Prakash Sep 2015 B2
9149051 Prakash Oct 2015 B2
9358264 Ibarra Jun 2016 B2
9457009 Guthrie Oct 2016 B2
9492379 Park Nov 2016 B2
9510611 Purkayastha Dec 2016 B2
9629795 Krammer Apr 2017 B2
9636373 Akao May 2017 B1
9775822 Prasad Oct 2017 B2
9844576 Brownell Dec 2017 B2
9848624 Ley Dec 2017 B2
9889107 Guthrie Feb 2018 B2
9962356 Prasad May 2018 B2
10188125 Ozato Jan 2019 B2
10376521 Zaworotko Aug 2019 B2
10420744 Prasad Sep 2019 B2
10602758 Dubois Mar 2020 B2
10624372 Reichelt Apr 2020 B2
10772340 Hotta Sep 2020 B2
10780170 Purkayastha Sep 2020 B2
10798961 Marcq Oct 2020 B2
10849339 Prakash Dec 2020 B2
10874130 Kim Dec 2020 B2
10952458 Purkayastha Mar 2021 B2
10973794 Forbes Apr 2021 B2
11000497 Prasad May 2021 B2
20010051195 Miljkovic Dec 2001 A1
20020068123 Verhagen Jun 2002 A1
20020187239 Miljkovic Dec 2002 A1
20020197386 Hiramoto Dec 2002 A1
20030003212 Chien Jan 2003 A1
20030008943 Slone Jan 2003 A1
20030045473 Sarama Mar 2003 A1
20030138537 Bailey Jul 2003 A1
20030172392 Mendu Sep 2003 A1
20040086619 Zhong May 2004 A1
20040213881 Chien Oct 2004 A1
20050079232 Offord-Cavin Apr 2005 A1
20050106215 Offord-Cavin May 2005 A1
20050220868 Lahl Oct 2005 A1
20060083838 Jackson Apr 2006 A1
20060263475 Jani Nov 2006 A1
20060280835 Jani Dec 2006 A1
20060286202 Boghani Dec 2006 A1
20070029258 Takeda Feb 2007 A1
20070054023 Bingley Mar 2007 A1
20070082106 Lee Apr 2007 A1
20070116800 Prakash May 2007 A1
20070116823 Prakash May 2007 A1
20070116828 Prakash May 2007 A1
20070116829 Prakash May 2007 A1
20070116838 Prakash May 2007 A1
20070116839 Prakash May 2007 A1
20070128311 Prakash Jun 2007 A1
20070292582 Prakash Dec 2007 A1
20080014331 Badalov Jan 2008 A1
20080063748 Massey Mar 2008 A1
20080107787 Prakash May 2008 A1
20080226788 Chang Sep 2008 A1
20080226790 Johnson Sep 2008 A1
20080261916 Jaszberenyi Oct 2008 A1
20080292764 Prakash Nov 2008 A1
20080292765 Prakash Nov 2008 A1
20080292775 Prakash Nov 2008 A1
20090004360 Bingley Jan 2009 A1
20090053378 Prakash Feb 2009 A1
20100028325 Rocabayera Bonvila Feb 2010 A1
20100099857 Evans Apr 2010 A1
20100160224 Thomas Jun 2010 A1
20100297327 Stangle Nov 2010 A1
20100330244 Nonaka Dec 2010 A1
20110033525 Liu Feb 2011 A1
20110091394 Abelyan Apr 2011 A1
20110104353 Lee May 2011 A1
20110160311 Prakash Jun 2011 A1
20110189360 Yoo Aug 2011 A1
20110195161 Upreti Aug 2011 A1
20110195170 Shigemura Aug 2011 A1
20110293538 Ley Dec 2011 A1
20120041078 Tachdjian Feb 2012 A1
20120058236 Fosdick Mar 2012 A1
20120064221 Given Mar 2012 A1
20120076899 Evans Mar 2012 A1
20120156351 Miyazawa Jun 2012 A1
20120177602 New Jul 2012 A1
20120196019 Shi Aug 2012 A1
20120201935 Krohn Aug 2012 A1
20130039932 Park Feb 2013 A1
20130040036 Zeller Feb 2013 A1
20130071521 Lee Mar 2013 A1
20130209658 Spelman Aug 2013 A1
20130251881 Mutilangi Sep 2013 A1
20130274351 Markosyan Oct 2013 A1
20130316066 Brown Nov 2013 A1
20140004215 Brownell Jan 2014 A1
20140094453 Tachdjian Apr 2014 A1
20140155359 Broze Jun 2014 A1
20140171519 Prakash Jun 2014 A1
20140206634 Liu Jul 2014 A1
20140295049 Ragot Oct 2014 A1
20140302180 Chapal Oct 2014 A1
20140309294 Erfurt Oct 2014 A1
20140342078 Hayes Nov 2014 A1
20150017284 Prakash Jan 2015 A1
20150050410 Luo Feb 2015 A1
20150125587 Asano May 2015 A1
20150189904 Prakash Jul 2015 A1
20150223510 Lee Aug 2015 A1
20150289548 Given Oct 2015 A1
20150320101 Walton Nov 2015 A1
20150328179 Nakashima Nov 2015 A1
20150366253 Shi Dec 2015 A1
20160100689 Wang Apr 2016 A1
20160113316 Nachbagauer Apr 2016 A1
20160165941 Hofmekler Jun 2016 A1
20160183574 Chen Jun 2016 A1
20160213039 Kumar Jul 2016 A1
20160242452 Mutilangi Aug 2016 A1
20160309761 Brower, III Oct 2016 A1
20160316797 Piorkowski Nov 2016 A1
20170006901 Carlson Jan 2017 A1
20170055548 Chakraborty Mar 2017 A1
20170095443 Luo Apr 2017 A1
20170105432 Karanewsky Apr 2017 A1
20170119032 Patron May 2017 A1
20170119033 Liu May 2017 A1
20170143012 San Miguel May 2017 A1
20170156374 Ackilli Jun 2017 A1
20170172191 Prakash Jun 2017 A1
20170183326 Kimoto Jun 2017 A1
20170273338 Lee Sep 2017 A1
20170295827 Prakash Oct 2017 A1
20170303574 Luo Oct 2017 A1
20170354175 Karanewsky Dec 2017 A1
20170362268 Carlson Dec 2017 A1
20180000133 Izumi Jan 2018 A1
20180002306 Jiang Jan 2018 A1
20180086751 Karanewsky Mar 2018 A1
20180092381 Brijwani Apr 2018 A1
20180103670 Recenti Apr 2018 A1
20180168212 Markosyan Jun 2018 A1
20180177216 Markosyan Jun 2018 A1
20180263269 Prakash Sep 2018 A1
20180289042 Bell Oct 2018 A1
20180296678 Prakash Oct 2018 A1
20190116835 Prakash Apr 2019 A1
20190142043 Prakash May 2019 A1
20190175499 Zhang Jun 2019 A1
20190274985 Hotta Sep 2019 A1
20190313669 Dubois Oct 2019 A1
20200009208 Hwang Jan 2020 A1
20200023021 Lewis Jan 2020 A1
20200054058 Prakash Feb 2020 A1
20200085778 Yamamoto Mar 2020 A1
20200138056 Graz May 2020 A1
20200138765 Prasad May 2020 A1
20200154737 Dubois May 2020 A1
20200196649 Mitchell Jun 2020 A1
20200197342 Russo Jun 2020 A1
20200237845 Suzuki Jul 2020 A1
20200275682 Chakraborty Sep 2020 A1
20200305483 Gan Oct 2020 A1
20200345049 Galano Nov 2020 A1
20210037851 Fraser Feb 2021 A1
20210051976 Fraser Feb 2021 A1
20210084949 Banavara Mar 2021 A1
20210092986 Dubois Apr 2021 A1
20210128600 Rauch May 2021 A1
20210153536 Ozato May 2021 A1
20210236450 Guthrie Aug 2021 A1
20210260013 Lee Aug 2021 A1
20210267243 Peterson Sep 2021 A1
Foreign Referenced Citations (155)
Number Date Country
1085073 Apr 1994 CN
1100894 Apr 1995 CN
1336333 Feb 2002 CN
1651398 Aug 2005 CN
1253099 Apr 2006 CN
100341500 Oct 2007 CN
102381974 Mar 2012 CN
102771751 Nov 2012 CN
102860438 Jan 2013 CN
104397785 Mar 2015 CN
102924544 Apr 2015 CN
103656627 Sep 2015 CN
103874411 Jun 2016 CN
106138298 Nov 2016 CN
107184482 Sep 2017 CN
107455718 Dec 2017 CN
29603759 May 1996 DE
29808384 Aug 1998 DE
0730830 Sep 1996 EP
1186297 Mar 2002 EP
1903890 Apr 2008 EP
1716757 Jul 2009 EP
1925208 Dec 2011 EP
2340719 Feb 2014 EP
2896301 Jun 2016 EP
2643007 Aug 2016 EP
3052074 Aug 2016 EP
2625962 Jun 2017 EP
3188604 Jul 2017 EP
3257507 Dec 2017 EP
3264919 Jan 2018 EP
3097790 May 2018 EP
2409696 Jun 2018 EP
2753188 Jan 2019 EP
2856883 Mar 2019 EP
2692243 Jun 2019 EP
3397072 Jul 2019 EP
3513663 Jul 2019 EP
3169166 Aug 2019 EP
3524062 Aug 2019 EP
2934181 Sep 2019 EP
2124647 Dec 2019 EP
3228195 Jan 2020 EP
3544445 May 2020 EP
2138067 Jun 1976 FR
2348104 May 1999 GB
54147976 Nov 1979 JP
63173531 Jul 1988 JP
0195739 Apr 1989 JP
0427374 Jan 1992 JP
04145048 May 1992 JP
0638723 Feb 1994 JP
07123921 May 1995 JP
07135938 May 1995 JP
0823939 Jan 1996 JP
0994080 Apr 1997 JP
09221667 Aug 1997 JP
09266767 Oct 1997 JP
10179079 Jul 1998 JP
10183164 Jul 1998 JP
10248501 Sep 1998 JP
119189 Jan 1999 JP
11299473 Nov 1999 JP
2000063827 Feb 2000 JP
2000308477 Nov 2000 JP
2002021938 Jan 2004 JP
2004528050 Sep 2004 JP
2006006318 Jan 2006 JP
2009517022 Apr 2009 JP
2009523407 Jun 2009 JP
2010521166 Jun 2010 JP
2011168543 Sep 2011 JP
2012005483 Jan 2012 JP
2012240949 Dec 2012 JP
2011071179 Apr 2013 JP
2015506718 Mar 2015 JP
2015511498 Apr 2015 JP
2016084887 Sep 2017 JP
2018085964 Jun 2018 JP
0710115 Jun 2020 JP
6710115 Jun 2020 JP
2019230013 Jun 2020 JP
101500485 Mar 2015 KR
12011000255 Jul 2011 PH
1998042209 Oct 1998 WO
1999030576 Jun 1999 WO
2000030464 Jun 2000 WO
2000062628 Oct 2000 WO
2000069282 Nov 2000 WO
2001097624 Dec 2001 WO
2002041700 May 2002 WO
02100192 Dec 2002 WO
2002096852 Dec 2002 WO
2007013616 Feb 2007 WO
2007061753 May 2007 WO
2007061795 May 2007 WO
2007149672 Dec 2007 WO
2008057965 May 2008 WO
2008093892 Aug 2008 WO
2008147723 Dec 2008 WO
2008147725 Dec 2008 WO
2009012051 Jan 2009 WO
2010038911 Apr 2010 WO
11094423 Aug 2011 WO
2011094423 Aug 2011 WO
2011105561 Sep 2011 WO
2011106114 Sep 2011 WO
2011112892 Sep 2011 WO
2012083251 Jun 2012 WO
2012107205 Aug 2012 WO
2012109506 Aug 2012 WO
2012166164 Dec 2012 WO
2013096420 Jun 2013 WO
2013148177 Oct 2013 WO
2014104408 Jul 2014 WO
2014146135 Sep 2014 WO
2014153000 Sep 2014 WO
2015023928 Feb 2015 WO
2015024218 Feb 2015 WO
2015117011 Aug 2015 WO
2016036578 Mar 2016 WO
2016049236 Mar 2016 WO
2016073251 May 2016 WO
16085919 Jun 2016 WO
16085924 Jun 2016 WO
16086233 Jun 2016 WO
WO-2016100689 Jun 2016 WO
17053980 Mar 2017 WO
2017059414 Apr 2017 WO
2017095932 Jun 2017 WO
17120480 Jul 2017 WO
17189994 Nov 2017 WO
2017196933 Nov 2017 WO
2018013739 Jan 2018 WO
2018102447 Jun 2018 WO
2019071182 Apr 2019 WO
2019071187 Apr 2019 WO
2019071188 Apr 2019 WO
2019071220 Apr 2019 WO
2019071254 Apr 2019 WO
19177634 Sep 2019 WO
2019177634 Sep 2019 WO
19222601 Nov 2019 WO
2020172276 Aug 2020 WO
2020202193 Oct 2020 WO
2020237060 Nov 2020 WO
2021038830 Mar 2021 WO
2021038832 Mar 2021 WO
2021049864 Mar 2021 WO
2021081417 Apr 2021 WO
2021090989 May 2021 WO
2021091322 May 2021 WO
2021091327 May 2021 WO
2021125070 Jun 2021 WO
2021132439 Jul 2021 WO
Non-Patent Literature Citations (183)
Entry
Matsumoto R. L. T., et al. (2009) Effects of maté tea (Ilex paraguariensis) ingestion on mRNA expression of antioxidant enzymes, lipid peroxidation, and total antioxidant status in healthy young women. J. Agric. Food Chem. 57, 1775-1780. DOI:10.1021/jf803096g.
Mello F. W., et al. (2018) Maté consumption association with upper aerodigestive tract cancers: a systematic review and meta-analysis. Oral Oncol. 82, 37-47 [plus supplementary data]. DOI:10.1016/j.oraloncology.2018.04.023.
Messina D., et al. (2017) Maté tea and lipid profile in overweight women under caloric restriction. Ann Nutr. Metab. 71, 384 [abstract 144-1131] DOI:10.1159/000480486.
Mikulasova M., et al. (2005) Genotoxic effects of the hydroxycinnamic acid derivatives—caffeic, chlorogenic and cichoric acids. Biologia (Bratisl.) 60, 275-279.
Minuzzi Becker A., et al. (2019) Spray-dried yerba mate extract capsules: clinical evaluation and antioxidant potential in healthy individuals. Plant oods Hum. Nutr. 74, 495-500 [plus supplementary tables]. DOI:10.1007/s11130-019-00764-4.
Miranda D. D. C., et al. (2008) Protective effects of mate tea (Ilex paraguariensis) on H2O2-induced DNA damage and DNA repair in mice. Mutagenesis 23, 261-265. DOI:10.1093/mutage/gen011.
Monteiro M., et al. (2007) Chlorogenic acid compounds from coffee are differentially absorbed and metabolized in humans. J. Nutr. 137, 2196-2201. DOI:10.1093/jn/137.10.2196.
Moura de Oliveira D., et al. (2017) Bioavailability of chlorogenic acids in rats after acute ingestion of maté tea (Ilex paraguariensis) or 5-caffeoylquinic acid. Eur. J Nutr. 56, 2541-2556. DOI:10.1007/s00394-016-1290-1.
Nakamura S., et al. (2006) [Pharmacokinetics of chlorogenic acids absorbed in human plasma and their metabolites following oral ingestion of coffee drink]. Yakuri To Chiryo [Jpn Pharmacol Ther.] 34, 1239-1246.
Naylor L. H., et al. (2021) Acute dose-response effect of coffee-derived chlorogenic acids on the human vasculature in healthy volunteers: a randomized controlled trial. Am. J. Clin. Nutr. 113, 370-379. DOI:10.1093/ajcn/nqaa312.
Nowacki L. C., et al. (2021) Ilex paraguariensis extract as an alternative to pain medications. Acta Pharm. 71, 383-398. DOI:10.2478/acph-2021-0029.
Ochiai R., et al. (2019) Effect of chlorogenic acids on cognitive function in mild cognitive impairment: a randomized controlled crossover trial. J. Alzheimers Dis. 72, 1209-1216 [plus supplementary tables]. DOI:10.3233/jad-190757.
Olthof M. R., et al. (2001a) Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concenliations in humans. Am. J. Clin. Nutr. 73, 532-538. DOI:10.1093/ajcn/73.3.532.
Olthof M. R., et al. (2001b) Chlorogenic acid and caffeic acid are absorbed in humans. J. Nutr. 131, 66-71. DOI:10.1093/jn/131.1.66.
Olthof M. R., et al. (2003) Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J. Nutr. 133, 1806-1814 [erratum, 133, 2692]. DOI:10.1093/jn/133.6.1806.
Onakpoya I. J., et al. (2015) The effect of chlorogenic acid on blood pressure: a systematic review and meta-analysis of randomized clinical trials. J. Hum. Hypertens. 29, 77-81 [plus supplementary data]. DOI:10.1038/ihh.2014.46.
Park I., et al. (2017) Effects of subacute ingestion of chlorogenic acids on sleep architecture and energy metabolism through activity of the autonomic nervous system: a randomised, placebo-controlled, double-blinded cross-over trial. Br. J. Nutr. 117, 979-984. DOI:10.1017/S0007114517000587.
Pereira Panza V., et al. (2019) Effect of mate tea (Ilex paraguariensis) on the expression of the leukocyte NADPH oxidase subunit p47phox and on circulating inflammatory cytokines in healthy men: a pilot study. Int. J. Food Sci. Nutr. 70, 212-221DOI:10.1080/09637486.2018.1486393.
Plumb G. W., et al. (1999) Metabolism of chlorogenic acid by human plasma, liver, intestine and gut microflora. J. Sci. Food Agric. 79, 390-392. DOI:10.1002/(SICI)1097-0010(19990301)79:3<390::AID-JSFA258>3.0.CO;2-0.
Prakash et al., “Catalytic Hydrogenation of the Sweet Principles of Stevia rebaudiana, Rebaudioside B, Rebaudioside C, and Rebaudioside D and Sensory Evaluation of Their Reduced Derivatives”, Int. J. Mol. Sci. 2012, 13, 15126-15136; doi:10.3390/ijms131115126.
Renouf M., et al. (2014) Dose-response plasma appearance of coffee chlorogenic and phenolic acids in adults. Mol. Nutr. Food Res. 58, 301-309. DOI:10.1002/mnfr.201300349.
Richling E., et al. (2012) Dose-response relationship of chlorogenic acids in humans. Naunyn Schmiedebergs ArchPharmacol. 385, S75 [abstract 327]. DOI:10.1007/s00210-012-0736-0.
Rocha D. S., et al. (2018) Effect of yerba mate (Ilex paraguariensis) extract on the metabolism of diabetic rats. Biomed. Pharmacother. 105, 370-376 [plus supplementary figure]. DOI:10.1016/j.biopha.2018.05.132.
Rogerio De Sousa W., et al. (2019) Evaluation of reproductive toxicology of aqueous extract of yerba mate (Ilex paraguariensis A. St.-Hil.), a traditional South American beverage. J. Med. Food 22, 97-101. DOI:10.1089/imf.2018.0060.
Sanchez Boado L., et al (2018) Effects of Ilex paraguariensis polyphenols on magnesium absortion and iron bioavailability: preliminary study. J. Food Res. 7, 114-126. DOI:10.5539/jfr.v7n2p114.
Sarria B., et al. (2020a) Yerba mate may prevent diabetes according to a crossover, randomized, controlled study in humans. Proc. Nutr. Soc. 79, OCE2, E245 DOI:10.1017/S0029665120001937.
Sarria B., et al. (2020b) Yerba mate improves cardiovascular health in normocholesterolemic and hypercholesterolemic subjects. Proc. Nutr. Soc. 79, OCE2, E635. DOI:10.1017/S0029665120005844.
Shinomiya K., et al. (2004) Effects of chlorogenic acid and its metabolites on the sleep-wakefulness cycle in rats. Eur. J. Pharmacol. 504, 185-189. DOI:10.1016/j.ejphar.2004.09.054.
Simao Do Carmo L., et al. (2013) The effects of yerba maté (Ilex paraguariensis) consumption on IL-1, IL-6, TNF-α and IL-10 production by bone marrow cells in Wistar rats fed a high-fat diet. Int J Vitam Nutr Res 83, 26-35. DOI:10.1024/0300-9831/a000142.
Sirima Puangpraphant et al: “Dicaffeoylquinic acids in Verba mate (Ilex paraguariensis St. Hilaire) inhibit NF-&kgr;B nucleus translocation in macrophages and induce apoptosis by activating caspases-8 and -3 in human colon cancer cells”, Molecular Nutrition & Food Research, vol. 55, No. 10, Oct. 8, 2011 (Oct. 8, 2011), pp. 1509-1522, XP055175515, ISSN: 1613-4125, DOI: 10.1002/mnfr.201100128.
Song Z., et al. (2014) [Effect of chlorogenic acid at high dose on expression of hepatic inflammatory cytokines mRNA induced by lipopolysaccharides]. Ying Yang Xue Bao [Acta Nutr. Sin.] 36, 481-485.
Souza S. J., et al. (2017) Effect of chocolate and mate tea on the lipid profile of individuals with HIV/AIDS on antiretroviral therapy: A clinical trial. Nutrition 43-44, 61-68. DOI:10.1016/j.nut.2017.06.017.
Stalmach A., et al. (2009) Metabolite profiling of hydroxycinnamate derivatives in plasma and urine after the ingestion of coffee by humans: identification of biomarkers of coffee consumption. Drug Metab. Dispos. 37, 1749-1758. DOI:10.1124/dmd.109.028019.
Stalmach A., et al. (2010) Bioavailability of chlorogenic acids following acute ingestion of coffee by humans with an ileostomy. Arch. Biochem. Biophys. 501, 98-105. DOI:10.1016/j.abb.2010.03.005.
Stich H. F., et al. (1981) A comparative genotoxicity study of chlorogenic acid (3-O-caffeoylquinic acid). Mutat. Res. 90, 201-212. DOI:10.1016/0165-1218(81)90001-X.
Suzuki A., et al. (2006) Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats. J. Hypertens. 24, 1065-1073. DOI:10.1097/01.hjh.0000226196.67052.c0.
U.S. FDA (1993) Appendix I. Table 14. Conversion table for test chemical treatment doses used in PAFA. In Priority Based Assessment of Food Additives (PAFA) Database. U.S. Food and Drug Administration (U.S. FDA), Center for Food Safety & Applied Nutrition (CFSAN), Washington, DC, p. 58.
U.S. FDA (2018) Part 182—Substances generally recognized as safe. Section §182.20—Essential oils, oleoresins (solvent-free), and natural extractives (including distillates). In: U.S. Code of Federal Regulations (CFR). Title 21: Food and Drugs. (U.S. Food and Drug Administration). U.S. Government Printing Office (GPO), Washington, DC.
Vargas Alves R. J., et al. (2008) The evaluation of maté (Ilex paraguariensis) genetic toxicity in human lymphocytes by the cytokinesis-block in the micronucleus assay. Toxicol. In Vitro 22, 695-698. DOI:10.1016/j.tiv.2007.11.005.
Wang Y., et al. (2018) [Effects of chlorogenic acid on growth performance, serum immunoglobulins, intestinal mucosa morphology, digestive and absorptive capacity of piglets]. Chin. J. Anim. Nutr. 30, 1136-1145 [DOI:10.7506/spkx1002-6630-201709026.
Wantanabe T., et al. (2019) Coffee abundant in chlorogenic acids reduces abdominal fat in overweight adults: a randomized, double-blind, controlled trial. Nutrients 11, 1617 [13pp]. DOI:10.3390/nu11071617.
Wei Z.-M., et al. (2010) [Clinical tolerability of 1,5-dicaffeoylquinic acid tablets]. Zhongguo Xin Yao Za Zhi [Chin. J. New Drugs] 19, 106-108.
Wnuk M., et al. (2009) Evaluation of the cyto- and genotoxic activity of yerba mate (Ilex paraguariensis) in human lymphocytes in vitro. Mutat. Res. 679, 18-23. DOI:10.1016/j.mrgentox.2009.07.017.
Yang B., et al. (2005) Metabolic profile of 1,5-dicaffeoylquinic acid in rats, an in vivo and in vitro study. Drug Metab. Dispos. 33, 930-936. DOI:10.1124/dmd.104.002154.
Yara Queiroz et al: The Chlorogenic Acid and Caffeine Content of Verba Mate (Ilex paraguariensis) Beverages11, Jan. 1, 2005 (Jan. 1, 2005), pp. 91-95, XP055715126, Retrieved from the Internet: URL:https://media.enfasis.com/adjuntos/146 /documentos/000/134/0000134821.pdf [retrieved on Jul. 15, 2020].
Yu S., et al. (2015) Yerba mate (Ilex paraguariensis) improves microcirculation of volunteers with high blood viscosity: a randomized, double-blind, placebo-controlled trial. Exp. Gerontol. 62, 14-22 [plus supplementary tables]. DOI:10.1016/j.exger.2014.12.016.
Zhu Y., et al. (2017) [Effect of caffeine and chlorogenic acid on body weight, lipid accumulation and the expression of lipid metabolism-related genes in high-fat diet-fed mice]. Shipin Kexue [Food Sci.] 38, 162-167 DOI:10.7506/spkx1002-6630-201709026.
Zuniga L. Y., et al. (2018) Effect of chlorogenic acid administration on glycemic control, insulin secretion, and insulin sensitivity in patients with impaired glucose tolerance. J. Med. Food 21, 469-473. DOI:10.1089/jmf.2017.0110.
Arthur, R., ‘“The stevia story has changed!’ PureCircle on the evolution of the natural sweetener,” Mar. 11, 2019, Beveragedaily.com.
Naimi, et al., “Rosemary Extract as a Potential Anti-Hyperglycemic Agent: Current Evidence and Future Perspectives”, Sep. 1, 2017, Nutrients; vol. 9, Issue 9, pp. 1-19.
Nalte, YK, et al., Solubility Enhancement of Nevirapine by Cocrystallisation Technique. Journal of Pharmacy Research. Aug. 21, 2015, vol. 9, No. 8; pp. 556-561. ISSN:0974-6943.
Nguyen et al., “Facile preparation of water soluble curcuminoids extracted from turmeric (Curcuma longa L.) power by using steviol glucosides,” Food Chemistry, 2017, 214, 366-373.
Nicoud, et al., “Estimation of the solubility of metastable polymorphs: A critical review,” Cryst. Growth Des., 2018.
Notice of Opposition in EP2934181.
Ohta et al., “Characterization of Novel Steviol Glycosides from Leaves of Stevia rebaudiana Morita,” 2010, J. Appl. Glycosci., 57, 199-209.
Prakash Indra et al: “Synthesis and Sensory Evaluation of ent-Kaurane Diterpene Glycosides”, Molecules, [Online] vol. 17, No. 8, Jan. 1, 2012 (Jan. 1, 2012), pp. 8908-8916, XP055839039, DOI:10.3390/molecules17088908 Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC6268950/pdf/molecules-17-08908.pdf> [retrieved on Aug. 5, 2021].
Prakash, “Characterization and sensory evaluation of a hexa B-D-glucopyranosyl diterpene from Stevia rebaudiana,” Natural Products Communications, 2013, 8:1523-1526.
Prakash, et al., “Development of novel functional confectionery using low reduced sugar,” Indian Journal of Drugs, 2016, 4(4), 141-148.
Rogers et al., “Changes to the content of sugars, sugar alcohols, myo-inositol, carboxylic acids and inorganic anions in developing grains from different varieties of Robusta (Coffea canephora) and Arabica (C. arabica) coffees,” Plant Science, 1999, 149, 115-123.
Roy, G., “Bitterness: reduction and inhibition,” Trends Food Sci Tech, 1992, 3, 85-91.
Schwarz et al., “Investigation of plant extracts for the protection of processed foods against lipid oxidation.” Eur Food Res Technol, 2001, 212:319-328.
Shibata et al., “Glucosylation of steviol and steviol-glucosides in extracts from Stevia rebaudiana Bertoni,” Plant Physiol., 1991, 95, 152-156.
Shiraishi et al., “Taste-Masking Effect of Chlorogenic Acid (CGA) on Bitter Drugs Evaluated by Taste Sensor and Surface Plasmon Resonance on the Basis of CGA-Drug Interactions,” 2017, 65(2):127-133, Chem Pharm Bull (Tokyo).
Standard Method Performance Requirements (SMPRs) for Determination of Phenolic Compounds in Dietary Supplements and Dietary Ingredients Containing Echinacea, Sep. 22, 2017, AOAC International.
Stukelj, et al., “Direct measurement of amorphous solubility,” Analytical Chemistry, 2019.
Suarez-Quiroz et al., “Isolation of green coffee chlorogenic acids using activated carbon,” Journal of Food Composition and Analysis, 2014, 33:55-58.
SUNUP® Commercially available stevia sweetened green coffee bean beverage, purchased Jun. 2018.
Sweet Drops™ Liquid Stevia Product, 2012.
Tanaka, O., “Improvement of taste of natural sweeteners,” Pure & Appl. Chem., 69(4):975-683, 1997.
Trugo et al., Chlorogenic Acid Composition of Instant Coffees, Analyst, Mar. 1984, vol. 109, pp. 263-266.
Tyrer, D., “The theory of solubility,” The Journal of Physical Chemistry, 1912.
Written Opinion of WO 2012/082587, dated Jun. 13, 2013.
Upreti, Mani et al., “Solubility Enhancement of Steviol Glycosides and Characterization of Their Inclusion Complexes with Gamma-Cyclodextrin”, Int. J. Mol. Sci. 2011, 12, 7529-7553.
Weidel et al., “A Rapid Method for Quantifying Chlorogenic Acid Levels in Potato Samples,” Journal of AOAC International, vol. 97, No. 3, Nov. 3, 2014.
Whole Foods 365 Stevia Extract Liquid, 2012.
Wildermuth et al., “Chlorogenic acid oxidation and its reaction with sunflower proteins to form green-colored complexes,” Comprehensive Reviews in Food Science and Food Safety, 2016, vol. 15, 829-843.
Abeywardena M. Y., et al. (2010) Acute administration of chlorogenic acid reduces blood pressure in the rat. Hypertension 55, 1493 [abstract 002]. DOI:10.1161/HYP.0b013e3181df4279.
Albas C. S., et al. (2014) Avaliação da genotoxicidade da Ilex paraguariensis (erva mate) pelo teste do micronúcleo / [Evaluation of the genotoxicity of Ilex paraguariensis (yerba mate) by micronucleus test]. Rev. Bras. Plantas Med. 16, 2, Suppl 1, 345-349 [Portuguese, English abstract]. DOI:10.1590/1983-084X/12_058.
Alkhatib A. and Atcheson, R. (2017) Yerba mate (Ilex paraguariensis) metabolic, satiety, and mood state effects at rest and during prolonged exercise. Nutrients 9, 882 [15pp]. DOI:10.3390/nu9080882.
Baeza Gema et al: “Dihydrocaffeic acid, a major microbial metabolite of chlorogenic acids, shows similar protective effect than a yerba mate phenolic extract against oxidative stress in HepG2 cells”, Food Research International, Elsevier, Amsterdam, NL, vol. 87, Jun. 17, 2016 (Jun. 17, 2016), pp. 25-33, XP029671195, ISSN: 0963-9969, DOI:10.1016/J.FOODRES.2016.06.011.
Balsan G., et al. (2019) Effect of yerba mate and green tea on paraoxonase and leptin levels in patients affected by overweight or obesity and dyslipidemia: a randomized clinical trial. Nutr. J. 18, 5 [10pp]. DOI:10.1186/s12937-018-0426-y.
Bariana D. S., et al. (1965) Chlorogenic acid: further evidence for its antigenic and allergenic activity. Nature 207, 1155-1157. DOI:10.1038/2071155a0.
Bidau C. J., et al. (2004) Evaluation of the genotoxicity of aqueous extracts of Ilex paraguariensis St. Hil. (Aquifoliaceae) using the Allium test. Cytologia 69, 109-117. DOI:10.1508/cytologia.69.109.
Boaventura B. C., et al (2012) Association of mate tea (Ilex paraguariensis) intake and dietary intervention and effects on oxidative stress biomarkers of dyslipidemic subjects. Nutrition 28, 657-664. DOI:10.1016/j.nut.2011.10.017.
Boaventura B. C., et al. (2013) Antioxidant potential of mate tea (Ilex paraguariensis) in type 2 diabetic mellitus and pre-diabetic individuals. J. Funct. Foods 5, 1057-1064. DOI:10.1016/j.jff.2013.03.001.
Boaventura B. C., et al. (2015) Effect of yerba mate (Ilex paraguariensis A. St. Hil.) infusion obtained by freeze concentration technology on antioxidant status of healthy individuals. LWT Food Sci. Technol. 62, 948-954. DOI:10.1016/j.lwt.2015.02.028.
Boaventura, B. C. B., et al. (2013). Enhancement of bioactive compounds content and antioxidant activity of aqueous extract of mate (Ilex paraguariensis A. St. Hil.) through freeze concentration technology. Food Research International, 53, 686e692.
Borges M. C., et al. (2013) The effect of mate tea (Ilex paraguariensis) on metabolic and inflammatory parameters in high-fat diet-fed Wistar rats. Int. J. Food Sci. Nutr. 64, 561-569. DOI:10.3109/09637486.2012.759188.
Bortoluzzi M.-C., et al. (2014) Frequency of micronucleus in oral epithelial cells after exposure to mate-tea in healthy humans. Med. Oral Patol. Oral Cir. Bucal. 19, e345-e349. DOI:10.4317/medoral.19570.
Carvalho Ribeiro M., et al (2017) The effects of roasted yerba mate (Ilex paraguariensis A. St. Hil.) consumption on glycemia and total serum creatine phosphokinase in patients with traumatic brain injury. J. Funct. Foods 28, 240-245. DOI:10.1016/j.jff.2016.11.
Chaube S. and Swinyard C. A. (1976) Teratological and toxicological studies of alkaloidal and phenolic compounds from Solanum tuberosum L. Toxicol. Appl. Pharmacol. 36, 227-237. DOI:10.1016/0041-008X(76)90002-8.
Chen J., et al. (2018) Dietary chlorogenic acid improves growth performance of weaned pigs through maintaining antioxidant capacity and intestinal digestion and absorption function. J. Anim. Sci. 96, 1108-1118. DOI:10.1093/jas/skx078.
Cuesta A., et al (2018) Efecto agudo del consumo de yerba mate (Ilex paraguariensis) sobre el ritmo cardíaco en pacientes derivados para estudio Holter [Acute effect of yerba mate (Ilex paraguariensis) consumption on heart rhythm in patients referred for Holter study] [epub ahead of print]. Arch. Cardiol. Mex. xxx, Jun. 2, 2018 [1-6] [Spanish, English abstract]. DOI:10.1016/j.acmx.2018.05.004.
De Andrade F., Coehlo de Albuquerque C. A., Maraschin M. and da Silva E. L. (2012) Safety assessment of yerba mate (Ilex paraguariensis) dried extract: results of acute and 90 days subchronic toxicity studies in rats and rabbits. Food Chem. Toxicol. 50, 328-334. DOI:10.1016/j.fct.2011.08.028.
De Meneses Fujii et al. (2014) Yerba Mate (Ilex paraguariensis) modulates NF-kappaB pathway and AKT expression in the liver of rats fed on a high-fat diet. Int. J. Food Sci. Nutr. 65, 967-976. DOI:10.3109/09637486.2014.945153.
De Morais E. C., et al. (2009) Consumption of yerba mate (Ilex paraguariensis) improves serum lipid parameters in healthy dyslipidemic subjects and provides an additional LDL-cholesterol reduction in individuals on statin therapy. J. Agric. Food Chem. 57, 8316-8324. DOI:10.1021/jf901660g.
Eklund A. (1975) Effect of chlorogenic acid in a casein diet for rats. Nutritional and pathological observations. Nutr. Metab. 18, 258-264. DOI:10.1159/000175603.
Enokuchi Y., et al. (2020) Effects of chlorogenic acids on menopausal symptoms in healthy women: a randomized, placebo-controlled, double-blind, parallel-group trial. Nutrients 12, 3757 [12pp]. DOI:10.3390/nu12123757.
Erk T., et al. (2012) Dose-dependent absorption of chlorogenic acids in the small intestine assessed by coffee consumption in ileostomists. Mol. Nutr. Food Res. 56, 1488-1500. DOI:10.1002/mnfr.201200222.
Folwarczna J., et al. (2012) Effects of caffeic and chlorogenic acids on bone mechanical properties in female rats. Bone 50, Suppl. 1, S158 [abstract PP306]. DOI:10.1016/j.bone.2012.02.495.
Fonseca C. A., et al (2000) Nontoxic, mutagenic, and clastogenic activities of mate-chimarrao (Ilex paraguariensis). J. Environ. Pathol. Toxicol. Oncol. 19, 333-346.
Frank J., et al. (2003) The dietary hydroxycinnamate caffeic acid and its conjugate chlorogenic acid increase vitamin E and cholesterol concentialions in Sprague-Dawley rats. J. Agric. Food Chem. 51, 2526-2531. DOI:10.1021/if026127k.
Freedman S. O., et al. (1961) Chlorogenic acid: an allergen in green coffee bean. Nature 192, 241-243. DOI:10.1038/192241a0.
Freedman S. O., et al. (1964) Antigenic and allergenic properties of chlorogenic acid man, rabbit, guinea pig. Can. Med. Assoc. J. 90, 473-474.
Gebara K. S., et al. (2020) A randomized crossover intervention study on the effect a standardized maté extract (Ilex paraguariensis A. St.-Hil.) in Men predisposed to cardiovascular risk. Nutrients, 13, 14 [14pp]. DOI:10.3390/nu13010014.
Gómez-Juaristi M., Martinez-López S., Sarria B., Bravo L. and Mateos R. (2018) Absorption and metabolism of yerba mate phenolic compounds in humans. Food Chem. 240, 1028-1038. DOI:10.1016/j.foodchem.2017.08.003.
Gonthier M.-P., et al. (2006) Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota in vitro. Biomed. Pharmacother. 60, 536-540. DOI:10.1016/j.biopha.2006.07.084.
Grzesiuk J. D., et al. (2012) Evaluation of mutagenicity and antimutagenicity of Ilex paraguariensi} A. St.-Hil.: Aquifoliaceae infusion on Allium cepa assay. Arq. Cienc. Saude UNIPAR 16, 73-78. DOI:10.25110/arqsaude.v16i2.2012.4840.
Gu R., et al. (2007) Simultaneous determination of 1,5-dicaffeoylquinic acid and its active metabolites in human plasma by liquid chromatography-tandem mass spectrometry for pharmacokinetic studies. J. Chromatogr. B. 852, 85-91. DOI:10.1016/j.jchromb.2006.12.055.
Hernandes L. C., et al. (2016) Cytotoxicity and genotoxicity of chlorogenic acid alone or associated with the demethylating drug 5-azacytidine in Jurkat cells. Toxicol. Lett. 258, Suppl. S, S56 [abstract OSC01-007]. DOI:10.1016/.toxlet.2016.06.1295.
IARC (1991) Mate. In Coffee, Tea, Mate, Methylxanthines and Methylglyoxal. IARC Working Group, Feb. 27-Mar. 6, 1990, Lyon. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 51, pp. 273-287. World Health Organization (WHO), International Agency for Research on Cancer (IARC).
IARC (2018) Drinking mate and very hot beverages. In Drinking Coffee, Mate, and Very Hot Beverages. Expert Opinions of IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, May 24-31, 2016, Lyon, France. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 116, pp. 427-496. Lyon, France: International Agency for Research on Cancer (IARC), Lyon, France.
Jin S., et al. (2015) Chlorogenic acid improves late diabetes through adiponectin receptor signaling pathways in db/db mice. PLoS ONE 10, e0120842 [15pp]. DOI:10.1371/journal.pone.0120842.
Kato M., et al. (2018) Effect of chlorogenic acid intake on cognitive function in the elderly: a pilot study. Evid. Based. Complement. Alternat. Med. 2018, Article ID 8608497 [8pp]. DOI:10.1155/2018/8608497.
Kim H. J., et al. (2012) Effect of green mate in overweight volunteers: a randomised placebo-controlled human study. J. Funct. Foods 4, 287-293. DOI:10.1016/j.jff.2011.12.005.
Kim S.-Y., et al. (2015) Anti-obesity effects of Yerba Mate (Ilex paraguariensis): a randomized, double-blind, placebo-controlled clinical trial. BMC Complement. Altern. Med. 15, 338 [8pp]. DOI:10.1186/s12906-015-0859-1.
Klein G. A., et al. (2011) Mate tea (Ilex paraguariensis) improves glycemic and lipid profiles of type 2 diabetes and pre-diabetes individuals: a pilot study. J Am. Coll. Nutr. 30, 320-332.
Kujawska M (2018) Yerba mate (Ilex paraguariensis) beverage: nutraceutical ingredient or conveyor for the intake of medicinal plants? Evidence from Paraguayan folk medicine. Evid. Based. Complement. Alternat. Med. 2018, Article ID 6849317 [17pp]. DOI:10.1155/2018/6849317.
Laird Layton L., et al. (1964) Pure chlorogenic acid is not allergenic in atopy to green coffee: A specific protein probably is involved. Nature 203, 188-189. DOI:10.1038/203188a0.
Leitão A. C. and Braga R. S. (1994) Mutagenic and genotoxic effects of mate (Ilex paraguariensis) in prokaryotic organisms. Braz. J. Med. Biol. Res. 27, 1517-1525.
Lin M., et al. (2013) Evaluation of the potential sensitization of chlorogenic Acid: a meta-analysis. Evid. Based. Complement. Alternat. Med. 2013, Article ID 208467 DOI:10.1155/2013/208467.
Liu B., et al. (2017) Preparation, phytochemical investigation, and safety evaluation of chlorogenic acid products from Eupatorium adenophorum. Molecules 22, 67 [12pp]. DOI:10.3390/molecules22010067.
Liu Z., et al. (2010) Evaluation of the immunosensitizing potential of chlorogenic acid using a popliteal lymph node assay in BALB/c mice Food Chem. Toxicol. 48, 1059-1065. DOI:10.1016/j.fct.2010.01.024.
Lorena Deladino et al: “Major Phenolics in Verba Mate Extracts (Ilex paraguariensis) and Their Contribution to the Total Antioxidant Capacity”, Food and Nutrition Sciences, vol. 04, Aug. 1, 2013 (Aug. 1, 2013), pp. 154-162, XP055588480, ISSN:2157-944X, DOI:10.4236/fns.2013.48A019.
Lowell F. C. (1965) Allergenicity of chlorogenic acid. J. Allergy 36, 308. DOI:10.1016/0021-8707(65)90091-2.
Marques V. X. and Farah A. (2010) Urinary excretion of chlorogenic acids and metabolites in humans after green mate (I. paraguariensis) consumption. FASEB J. 24, 1, Suppl., [abstract 922.1] DOI:10.1096/fasebj.24.1_supplement.922.1.
Ana Covarrubias-Cárdenas et al., “Antioxidant Capacity and UPLC-PDA ESI-MS Phenolic Profile of Stevia rebaudiana Dry Powder Extracts Obtained by Ultrasound Assisted Extraction”, Agronomy,vol. 8, No. 9, Aug. 31, 2018 (Aug. 31, 2018), p. 170.
Analysis of the chemical constituents of Stevia rebausiana and its sweetness Reb M structure, Mar. 20, 2012, Journal of Beijing University of Chemical Technology (Natural Science).
Anonymous, “Sparkling Organic Grapefruit Ginger Soda”, GNPD 2012, retrieved from www.gnpd.comDatabase accession No. 1790955.
Anonymous, “Stevia production process | Cargill no-calories sweeteners | Cargill”, Nov. 4, 2020 (Nov. 4, 2020), Retrieved from the Internet: URL:https://www.cargill.com/food-beverage/emea/stevia-based-sweeteners-production-process.
Anonymous, “Steviol Glycosides Based Table Sweetener”, GNPD14 Dec. 2018 (Dec. 14, 2018), Database accession No. 6205393.
Aranda Gonzalez, et al., “Effect of different drying methods on the composition of steviol glycosides in Stevia rebaudiana Bertoni leaves,” Int. Agrophys., 2017, 31, 139-144.
Augustijns and Brewster, “Solvent systems and their selection in pharmaceutics and biopharmaceutics,” Springer, 2009.
Bartoshuk et al., “Sweet Taste of Water Induced by Artichoke,” Dec. 1, 1972, Science, 178 (4064), 988-990.
Berte et al. (2011) J. Agric. Food Chem. 59: 5523-5527. (Year: 2011).
Brent, Rhea, “Investigating differences in solubility between crystalline and amorphous forms of pharmaceuticals,” AstraZeneca, Mat 2006.
Brittain, Harry, “Thermodynamic vs. kinetic solubility: knowing which is which,” American Pharmaceutical Review, 2014.
Chang, et al., “Stability studies of stevioside and Rebaudioside A in carbonated beverages,” J. Agric. Food Chem., 1983, 31, 409-412.
Chiou, et al., “A comparison of crystallisation approaches in spray drying,” Jounral of Food Engineering, 2008.
Cilliers, et al., “Total polyphenols in apples and ciders; correlation with chlorogenic acid,” Journal of Food Science, vol. 55, No. 5, 1990, pp. 1458-1459.
Clifford, “Chlorogenic acids and other cinnamates—nature, occurance, and dietary burden,” Journal of the Science of Food and Agriculture, 79:362-372 (1999).
Coquerel, Gerard, “Crystallization of molecular systems from solution: phase diagrams, supersturation, and other basic concepts,” Chem Soc Rev, 2014.
Craig et al., “Performance review of a fast HPLC-UV method for the quantification of chorogenic acids in green coffee bean extracts,” Talanta, 154 (2016) 481-485.
Crammer and R I Kan B: II Properties and syntheses of sweetening agents, Chemical Society Reviews, Royal Society of Chemistry, UK, vol. 6, Jan. 1, 1977 (Jan. 1, 1977), pp. 431-465, XP009150156, ISSN:0306-0012 p. 437, paragraph 2—p. 438, paragraph 1.
Cros et al., “Solvent Extraction of Oil and Chlorogenic Acid from Green Cofffee Part I: Equilibrium Data,” Journal of Food Engineering 10 (1989) 1-11.
Deladino L., et al., “Major phenolics in Yerba mate extracts(Ilex paraguariensis) and their contribution to the total antioxidant capacity,” Food and Nutritional Science, 4, 2013.
Douglass, et al., “Kinetics of dissolution of an amorphous solid,” J. Phys. Chem. B, 2018.
Dubois, G. E., et al., “Concentration-Response relationship of sweeteners,” ACS Syposium Series, 1991.
Edgar Naegele, “Determination of Chlorogenic Acid in Coffee Products According to DIN 10767,” Sep. 1, 2016, Agilent Technology, INC.
Fu et al., “Production of chlorogenic acid and its derivatives in hairy root cultures of Stevia rebaudiana,” Jan. 14, 2015, Journal of Agriculatural and Food Chemistry, 63(1):262-268.
Gawel-Beben et al., “Stevia rebuadiana Bert. Leaf extracts as a multifunctional source of natural antioxidants,” Molecules, Mar. 27, 2015.
Giordani, Antonio, “The amorphous form in drug development,” Crystal Forms, 2012.
Hancock, B. C., et al. “What is the true solubility advantage for amorphous pharmaceuticals?,” Pharm Res, 17:397-404, 2000.
Hernandez T et al., “Variations in the phenolic composition of fruit juices with different treatments,” European Food Research and Technology, vol. 204, No. 2, 1997, p. 151-155.
Hildebrand, Joel, “Theory of solubility,” Physical Review, 1923.
Islam, et al., “Particle crystallization during spray drying in humid air,” Journal of Food Engineering, 2010.
Jeon et al., “Contents of chlorogenic acids and caffeine in various coffee-related products,” Journal of Advanced Research, 17 (2019), 85-94.
Julia Y.Q. Low et al., “Psychophysical Evaluation of Sweetness Functions Across Multiple Sweeteners”, Chemical Senses.,vol. 42, No. 2, Oct. 20, 2016 (Oct. 20, 2016), p. 111-120.
Kellie P Burris et al, “Composition and Bioactive Properties of Yerba Mate (Ilex paraguariensis A. St.-Hil.): A Review”, Chillán Jun. 2012 (Jun. 2012), p. 268-275.
Kremr et al., “Unremitting Problems with Chlorogenic Acid Nomenclature: A Review,” Quim. Nova, vol. 39, No. 4, 530-533, 2016.
Kren, V., et al., “Glycosides in Medicine: The Role of Glycosidic Residue in Biological Activity”, Current Medicinal Chemistry, 2001, 8, 1313-1338.
Kroyer, G., “Stevioside and Stevia-sweetener in food: application, stability and interaction with food ingredients,” J. Verbr. Lebensm., 2010, 5:225-229.
Ky et al., “Camparison of Five Purification Methods for Chlorogenic Acids in Green Coffee Beans (Coffea sp.),” J. Agric. Food Chem. 1997, 45, 786-790, obtained from https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_6/b_fdi47-48/010010457.pdf.
Lee et al., “Chicoric acid: chemistry distribution, and production,” Frontiers in Chemistry, 2013, 1(40).
Liquid Stevia and Liquid Stevia (flavored) from Stevita Co., 2012.
Maietta et al., “Artichoke (Cynara cardunculus L. var. scolymus) waste as a natural source of carbonyl trapping and antiglycative agents,” Food Research International, 100 (2017) 780-790.
Masuda, et al., “Powder Technology Handbook,” Taylor & Francis, 2006.
Meilgaard MC, Civille GV, and Carr BT (2007). Sensory Evaluations Techniques, CRC Press, Boca Raton, FL.
Meinhart et al., “Analysis of chlorogenic acids isomers and caffeic acid in 89 herbal infusions (tea),” Journal of Food Composition and Analysis, 73 (2018) 76-82.
Meinhart et al., “Chlorogenic acid isomer contents in 100 plants commercialized in Brazil,” Food Research International, 99 (2017) 522-530.
Meireles et al., “Stevia (Stevia rebaudiana Bertoni):—Futuristic view of the sweeter side of life,” Floriculture, Ornamental and Plant Biotechnology vol. IV, 2006, Global Science Books.
Miura et al., “Molecularly imprinted polymer for chlorogenic acid by modified precipitation polymerization and its application to extraction of chlorogenic acid from Eucommia ulmodies leaves,” Journal of Pharmaceutical and Biomedical Analysis, 114 (2015) 139-144.
Murdande, et al., “Aqueous solubility of crytalline and amorphous drugs: challenges in measurement,” Pharmaceutical Development and Technology, 2011.
Murdande, et al., “Solubility Advantage of amorphous pharmaceuticals: I. A thremodynamic analysis,” Wiley InterScience, 2009.
Murshedkav, Tooba, “Effect of crystalline to amorphous coversion on solubility of cefuroxime axetil,” Univeristy of Rhode Island, 2002.
Song, “Lenalidomide-Gallic Acid Cocrystals with Constant High Solubility”, Crystal Growth & Design, 2015, 15, pp. 4869-4875.
Moeenfard, et al., “Quantification of Caffeoylquinic Acids in Coffee Brews by HPLC-DAD,” Journal of Analytical Methods in Chemistry, Dec. 21, 2014.
Phenolaeis.com Accessed Aug. 24, 2022 Palm Fruit Extract compositions and applications.
Phenolaeis.com Accessed Sep. 9, 2020 Palm Fruit Bioactives Complex.
Liu Na, et al., “Review on Stevia rebaudiana research abroad in 2015”, Sugar Crops of China. 2017, 39(1): 57-64, Only abstract in English.
Wang Shaojia, et al., “Progress of functional components in Stevia rebaudiand Bertoni”, Science and Technology of Food Industry. 2017, vol. 38, No. 20, Only abstract in English.
Journal of the Brewing Society of Japan, 1959, vol. 54, No. 4, pp. 239-242.
Pimpley et al. “The chemistry of chlorogenic acid from green coffee and its role in attenuation of obesity and diabetes” at https:// pubmed.ncbi.nim.nih.gov/32633686. (Year: 2020).
Related Publications (1)
Number Date Country
20190223482 A1 Jul 2019 US
Provisional Applications (2)
Number Date Country
62676722 May 2018 US
62569279 Oct 2017 US
Continuations (1)
Number Date Country
Parent PCT/US2018/054804 Oct 2018 US
Child 16374388 US